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In preparation for a legal implementation of EU-regulation 1829/2003, the Norwegian Scientific 
Committee for Food Safety (VKM) has been requested by the Norwegian Environment Agency 
(former Norwegian Directorate for Nature Management) and the Norwegian Food Safety Authority 
(NFSA) to conduct final food/feed and environmental risk assessments for all genetically modified 
organisms (GMOs) and products containing or consisting of GMOs that are authorized in the 
European Union under Directive 2001/18/EC or Regulation 1829/2003/EC. The request covers 
scope(s) relevant to the Gene Technology Act. The request does not cover GMOs that VKM already 
has conducted its final risk assessments on. However, the Agency and NFSA requests VKM to 
consider whether updates or other changes to earlier submitted assessments are necessary. 
 
The insect-resistant and herbicide-tolerant genetically modified maize 59122 x NK603 from Pioneer 
Hi-Bred International, Inc. (Unique Identifier DAS-59122-7 x MONØØ6Ø3-6) is approved under 
Regulation (EC) No 1829/2003 for food and feed uses, import and processing since 30 October 2009 
(Commission Decision 2009/815/EC).  
 
Genetically modified maize 59122 x NK603 has previously been risk assessed by the VKM Panel on 
Genetically Modified Organisms (GMO), commissioned by the Norwegian Food Safety Authority 
related to the EFSAs public hearing of the application EFSA/GMO/UK/2005/20 in 2007 (VKM 
2007a). In addition 59122 x NK603 has been evaluated by the VKM GMO Panel as single events and 
as a component of several stacked GM maize events (VKM 2005a,b,d, VKM 2007b,c, VKM 2008b,c, 
VKM 2009a,b, VKM 2012). 
  
The food/feed and environmental risk assessment of the maize 59122 x NK603 is based on 
information provided by the applicant in the application EFSA/GMO/UK/2005/20, and scientific 
comments from EFSA and other member states made available on the EFSA website GMO Extranet. 
The risk assessment also considered other peer-reviewed scientific literature as relevant.   
 
The VKM GMO Panel has evaluated 59122 x NK603 with reference to its intended uses in the 
European Economic Area (EEA), and according to the principles described in the Norwegian Food 
Act, the Norwegian Gene Technology Act and regulations relating to impact assessment pursuant to 
the Gene Technology Act, Directive 2001/18/EC on the deliberate release into the environment of 
genetically modified organisms, and Regulation (EC) No 1829/2003 on genetically modified food and 
feed. The Norwegian Scientific Committee for Food Safety has also decided to take account of the 
appropriate principles described in the EFSA guidelines for the risk assessment of GM plants and 
derived food and feed (EFSA 2011a), the environmental risk assessment of GM plants (EFSA 2010), 
selection of comparators for the risk assessment of GM plants (EFSA 2011b) and for the post-market 
environmental monitoring of GM plants (EFSA 2011c).  
 
The scientific risk assessment of maize 59122 x NK603 include molecular characterisation of the 
inserted DNA and expression of novel proteins, comparative assessment of agronomic and phenotypic 
characteristics, nutritional assessments, toxicology and allergenicity, unintended effects on plant 
fitness, potential for gene transfer, interactions between the GM plant and target and non-target 
organisms, effects on biogeochemical processes.  
 
It is emphasized that the VKM mandate does not include assessments of contribution to sustainable 
development, societal utility and ethical considerations, according to the Norwegian Gene Technology 
Act and Regulations relating to impact assessment pursuant to the Gene Technology Act. These 
considerations are therefore not part of the risk assessment provided by the VKM Panel on Genetically 
Modified Organisms.  
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The genetically modified maize stack 59122 x NK603 was produced by conventional breeding 
between inbred lines of maize containing the 59122 and NK603 events. The hybrid was developed to 
provide protection against certain coleopteran target pests, and to confer tolerance to glufosinate-
ammonium and glyphosate herbicides. 
 
 
Molecular characterisation  
Southern and PCR analyses has been performed and indicate that the recombinant inserts in the single 
maize events 59122 and NK603 are retained in maize stack 59122xNK603. Genetic stability of the 
inserts has previously been demonstrated in the parental lines 59122 and NK603. The level of 
Cry34Ab1/Cry35Ab1, PAT and CP4 EPSPS proteins in seed and forage from the stacked event were 
measured using ELISA and are comparable to the levels in the single events. Phenotypic analyses also 




Comparative analyses of data from field trials located at representative sites and environments in 
North America indicate that maize stack 59122 x NK603 is compositionally, agronomically and 
phenotypically equivalent to its conventional counterpart, with the exception of the introduced insect 
resistance and herbicide tolerance, conferred by the expression of the Cry34Ab1, Cry35Ab1, PAT and 
CP4 EPSPS proteins. Based on the assessment of available data, the VKM GMO Panel is of the 
opinion that conventional crossing of maize 59122 and NK603 to produce the hybrid 59122 x NK603 
does not result in interactions that cause compositional, agronomic and phenotypic changes that would 
raise safety concerns.  
 
Food and feed risk assessment 
Whole food feeding study has not been performed using 59122 x NK603 maize.  The applicant has, 
however, provided a nutritional study on broilers using the triple stacked event 59122 x 1507 x NK603 
maize as test material. Bioinformatics analyses have not revealed expression of any known ORFs in 
the parental maize lines, and none of the newly expressed proteins show resemblance to any known 
toxins or IgE allergens. Nor have the newly expressed proteins been reported to cause IgE mediated 
allergic reactions. Some studies have however indicated a potential role of Cry-proteins as adjuvants 
in allergic reactions. 
 
Acute and repeated toxicity tests in rodents have not indicated toxic effects of the newly expressed 
proteins. However, these tests do not provide any additional information about possible adverse effects 
of the stacked event maize 59122 x NK603. 
 
Based on the current knowledge, the VKM GMO Panel concludes that 59122 x NK603 maize is 
nutritionally equivalent to its conventional maize, and that it is unlikely that newly expressed proteins 
will introduce a toxic or allergenic potential of food/feed derived from maize 59122 x NK603 
compared to conventional maize. 
 
Environmental risk assessment 
The scope of the application EFSA/GMO/UK/2005/20 includes import and processing of maize stack 
59122 x NK603 for food and feed uses. Considering the intended uses of maize 59122 x NK603, 
excluding cultivation, the environmental risk assessment is concerned with accidental release into the 
environment of viable grains during transportation and processing, and indirect exposure, mainly 
through manure and faeces from animals fed grains from maize 59122 x NK603.  
 
Maize 59122 x NK603 has no altered survival, multiplication or dissemination characteristics, and 
there are no indications of an increased likelihood of spread and establishment of feral maize plants in 
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the case of accidental release into the environment of seeds from maize 59122 x NK603. Maize is the 
only representative of the genus Zea in Europe, and there are no cross-compatible wild or weedy 
relatives outside cultivation. The VKM GMO Panel considers the risk of gene flow from occasional 
feral GM maize plants to conventional maize varieties to be negligible in Norway. Considering the 
intended use as food and feed, interactions with the biotic and abiotic environment are not considered 
by the GMO Panel to be an issue. 
 
Overall conclusion 
The VKM GMO Panel has not identified toxic or altered nutritional properties of maize 59122 x 
NK603 or its processed products compared to conventional maize. Based on current knowledge, it is 
also unlikely that the Cry34Ab1 and Cry35Ab1 protein will increase the allergenic potential of food 
and feed derived from maize 59122 x NK603 compared to conventional maize varieties. The VKM 
GMO Panel likewise concludes that maize 59122 x NK603, based on current knowledge, is 
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I forbindelse med forberedelse til implementering av EU-forordning 1829/2003 i norsk rett, er 
Vitenskapskomiteen for mattrygghet (VKM) bedt av Miljødirektoratet (tidligere Direktoratet for 
naturforvalting (DN)) og Mattilsynet om å utarbeide endelige helse- og miljørisikovurderinger av alle 
genmodifiserte organismer (GMOer) og avledete produkter som inneholder eller består av GMOer 
som er godkjent under forordning 1829/2003 eller direktiv 2001/18, og som er godkjent for ett eller 
flere bruksområder som omfattes av genteknologiloven. Miljødirektoratet og Mattilsynet har bedt 
VKM om endelige risikovurderinger for de EU-godkjente søknader hvor VKM ikke har avgitt 
endelige risikovurderinger. I tillegg er VKM bedt om å vurdere hvorvidt det er nødvendig med 
oppdatering eller annen endring av de endelige helse- og miljørisikovurderingene som VKM tidligere 
har levert. 
 
Den insektsresistente og herbicidtolerante maishybriden 59122 x NK603 (unik kode DAS-59122-7 x 
MONØØ6Ø3-6) fra Pioneer Hi-Bred International ble godkjent til import, videreforedling og til bruk 
som mat og fôr under EU-forordning 1829/2003 i 2009 (søknad EFSA/GMO/UK/2005/20, 
Kommisjonsbeslutning 2009/815/EU).   
 
Maishybriden har tidligere vært vurdert av VKMs faggruppe for genmodifiserte organismer med 
hensyn på mulig helserisiko i forbindelse med EFSAs offentlige høring av søknaden i 2007 (VKM 
2007a). Foreldrelinjene 59122 og NK603 er også tidligere risikovurdert av VKM, både som enkelt-
eventer og i en rekke andre hybrider (VKM 2005a,b, VKM 2007b,c, VKM 2008b,c, VKM 2009a,b, 
VKM 2012). 
 
Risikovurderingen av den genmodifiserte maislinjen er basert på uavhengige vitenskapelige 
publikasjoner og dokumentasjon som er gjort tilgjengelig på EFSAs nettside EFSA GMO Extranet. 
Vurderingen er gjort i henhold til tiltenkt bruk i EU/EØS-området, og i overensstemmelse med 
miljøkravene i genteknologiloven med forskrifter, først og fremst forskrift om konsekvensutredning 
etter genteknologiloven. Videre er kravene i EU-forordning 1829/2003/EF, utsettingsdirektiv 
2001/18/EF (vedlegg 2,3 og 3B) og veiledende notat til Annex II (2002/623/EF), samt prinsippene i 
EFSAs retningslinjer for risikovurdering av genmodifiserte planter og avledete næringsmidler (EFSA 
2006, 2010, 2011a,b,c) lagt til grunn for vurderingen.  
 
Den vitenskapelige vurderingen omfatter transformeringsprosess og vektorkonstruksjon, 
karakterisering og nedarving av genkonstruksjonen, komparativ analyse av ernæringsmessig kvalitet, 
mineraler, kritiske toksiner, metabolitter, antinæringsstoffer, allergener og nye proteiner. Videre er 
agronomiske egenskaper, potensiale for utilsiktede effekter på fitness, genoverføring og effekter på 
ikke-målorganismer vurdert. 
 
Det presiseres at VKMs mandat ikke omfatter vurderinger av etikk, bærekraft og samfunnsnytte, i 
henhold til kravene i den norske genteknologiloven og dens konsekvensutredningsforskrift. Disse 
aspektene blir derfor ikke vurdert av VKMs faggruppe for genmodifiserte organismer. 
 
F1-hybriden 59122 x NK603 er resultat av konvensjonelle kryssinger mellom de genmodifiserte 
maislinjene 59122 og NK603. Kryssingene er utført for å utvikle en maishybrid med resistens mot 
visse skadegjørere i billeslekten Diabrotica, samt toleranse mot herbicider med virkestoff glufosinat-
ammonium og glyfosat. 
 
Foreldrelinjen 59122 uttrykker en ny type Bt-toksin, som er resultat av introduksjon av to cry-gener 
(cry34Ab1og cry35Ab1) fra B. thuringiensis stamme PS149B1. Proteinene virker sammen som et 
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binært toksin og gir plantene resistens mot angrep fra skadegjørere i slekten Diabrotica. I tillegg har 
maislinjen fått satt inn et pat-gen. 
 
Foreldrelinje NK603 uttrykker CP4-EPSPS-proteiner, som et resultat av introduksjon av cp4-
epspsgenet fra jordbakterien Agrobacterium tumefaciens. Genet koder for enzymet 5-
enolpyruvylsikimat-3-fosfatsyntetase, som omdanner fosfoenolpyruvat og sikimat-3-fosfat til 5-
enolpyruvylsikimat-3-fosfat, en viktig metabolitt i syntesen av aromatiske aminosyrer. I motsetning til 
plantens enzym er det bakterielle enzymet også aktivt ved nærvær av N-fosfonometylglycin (glyfosat). 
De transgene plantene vil derfor tolerere høyere doser av herbicider med virkestoff glyfosat 




Maishybriden 59122 x NK603 er dannet ved konvensjonell kryssing mellom maislinjene 59122 og 
NK603. Spaltingsdata og PCR-analyser indikerer at de innsatte strukturer nedarves stabilt, og at antall, 
struktur og organisering av disse genkonstruksjonene er ekvivalent med de som finnes i 
foreldrelinjene. Nivåene av Cry34Ab1-, Cry35Ab1-, PAT- og CP4 EPSPS-proteiner i vegetativt vev 




Feltforsøk over en vekstsesong i Nord-Amerika viser små eller ingen signifikante forskjeller mellom 
den transgene maishybriden 59122 x NK603 og korresponderende, nær-isogene kontrollhybrider med 
hensyn på ernæringsmessig, morfologiske og agronomiske karakterer. Det er funnet statistiske 
forskjeller i enkeltparametere, men verdiene for de enkelte analyserte komponentene ligger innenfor 
typiske verdier for andre maissorter som er rapportert i litteraturen.  Resultatene indikerer agronomisk 
og fenotypisk ekvivalens mellom 59122 x NK603 og umodifisert kontroll, og at de innsatte genene i 





Fôringsstudie med hel mat er ikke utført med mais 59122 x NK603. Ingen negative helseeffekter 
relatert til mais 59122 x 1507 x NK603 ble rapportert fra fôringsstudie med hel mat utført på broilere. 
Bioinformatikk-analyser viser ingen likheter mellom de introduserte proteinene og kjente toksiner 
eller IgE-allergener. Det er heller ikke dokumentert at noen av proteinene kan utløse IgE-medierte 
allergiske reaksjoner. Enkelte studier har derimot indikert at noen typer Cry-proteiner potensielt kan 
forsterke andre allergiske reaksjoner (virke som adjuvans). 
 
Akutte oral-eksponeringsstudier indikerer ingen toksisitet relatert til proteinene Cry34Ab1, Cry35Ab1, 
PAT og CP4 EPSPS. Denne typen studier gir derimot ingen tilleggsinformasjon om mulige 
helseskadelige egenskaper ved mais 59122 x NK603.  
 
Ut i fra dagens kunnskap konkluderer VKMs faggruppe for GMO at mais 59122 x NK603 er 
næringsmessig vesentlig lik konvensjonell mais, og at det er lite trolig at de nye proteinene vil 
introdusere et toksisk eller allergent potensiale i mat og fôr basert på mais 59122 x NK603 
sammenliknet med konvensjonelle maissorter.  
 
Miljørisiko 
Søknaden gjelder godkjenning av maishybrid 59122 x NK603 for import, prosessering og til bruk i 
næringsmidler og fôrvarer, og omfatter ikke dyrking. Med bakgrunn i tiltenkt bruksområde er 
miljørisikovurderingen avgrenset til mulige effekter av utilsiktet frøspredning i forbindelse med 
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transport og prosessering, samt indirekte eksponering gjennom gjødsel fra husdyr fôret med 
genmodifisert mais.  
 
Det er ingen indikasjoner på økt sannsynlighet for spredning, etablering og invasjon av maislinjen i 
naturlige habitater eller andre arealer utenfor jordbruksområder som resultat av frøspill i forbindelse 
med transport og prosessering. Risiko for utkryssing med dyrkede sorter vurderes av GMO panelet til 
å være ubetydelig. Ved foreskreven bruk av maislinjen 59122 x NK603 antas det ikke å være risiko for 
utilsiktede effekter på målorganismer, ikke-målorganismer eller på abiotisk miljø i Norge. 
 
Samlet vurdering  
VKMs faggruppe for GMO har ikke identifisert toksiske eller endrede ernæringsmessige egenskaper 
til mais 59122 x NK603 eller prosesserte produkter sammenliknet med konvensjonell mais. Basert på 
dagens kunnskap er det også lite trolig at Cry34Ab1 eller Cry35Ab1 proteinene vil øke det allergene 
potensialet til mat og fôr produsert fra mais 59122 x NK603 sammenliknet med konvensjonelle 
maissorter. Faggruppen finner at maishybrid 59122 x NK603, ut fra dagens kunnskap og omsøkt bruk, 
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Abbreviations and explanations 
 
 
ALS Acetolactate synthase, an enzyme that catalyses the first step in the synthesis 
of the branched-chain amino acids, valine, leucine, and isoleucine 
AMPA Aminomethylphosphonic acid, one of the primary degradation products of 
glyphosate 
ARMG   Antibiotic resistance marker gene  
BC Backcross. Backcross breeding in maize is extensively used to move a single 
trait of interest (e.g. disease resistance gene) from a donor line into the 
genome of a preferred or “elite” line without losing any part of the preferred 
lines existing genome. The plant with the gene of interest is the donor parent, 
while the elite line is the recurrent parent. BC1, BC2 etc. designates the 
backcross generation number. 
BLAST Basic Local Alignment Search Tool. Software that is used to compare 
nucleotide (BLASTn) or protein (BLASTp) sequences to sequence databases 
and calculate the statistical significance of matches, or to find potential 
translations of an unknown nucleotide sequence (BLASTx). BLAST can be 
used to understand functional and evolutionary relationships between 
sequences and help identify members of gene families.  
bp   Basepair 
Bt    Bacillus thuringiensis 
CaMV   Cauliflower mosaic virus 
Codex Set by The Codex Alimentarius Commission (CAC), an intergovernmental 
body to implement the Joint FAO/WHO Food Standards Programme. Its 
principle objective is to protect the health of consumers and to facilitate the 
trade of food by setting international standards on foods (i.e. Codex 
Standards)  
Cry Any of several proteins that comprise the crystal found in spores of Bacillus 
thuringiensis. Activated by enzymes in the insects midgut, these proteins 
attack the cells lining the gut, and subsequently kill the insect  
Cry34/35Ab1  Binary crystal protein containing of Cry34Ab1 and Cry35Ab1. 
Cry34Ab1  Cry34 class crystal protein from  Bacillus thuringiensis stamme 149B1. 
Cry35Ab1  Cry35 class crystal protein from  Bacillus thuringiensis stamme 149B1. 
CTP   Chloroplast transit peptide 
DAP    Days after planting 
DN Norwegian Directorate for Nature Management (Direktoratet for 
naturforvalting) 
DNA   Deoxyribonucleic acid 
DT50    Time to 50% dissipation of a protein in soil 
DT90    Time to 90% dissipation of a protein in soil 
dw    Dry weight 
dwt    Dry weight tissue 
EC    European Commission/Community 
ECB    European corn borer, Ostrinia nubilalis 
EFSA   European Food Safety Authority 
ELISA   Enzyme-linked immunosorbent assay 
EPSPS   5-enolpyruvylshikimate-3-phosphate synthase 
ERA    Environmental risk assessment 
E-score   Expectation score 
EU    European Union 
fa    Fatty acid 
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FAO   Food and Agriculture Organisation  
FIFRA  US EPA Federal Insecticide, Fungicide and Rodenticide Act  
Fitness Describes an individual's ability to reproduce successfully relative to that of 
other members of its population 
fw    Fresh weight 
fwt    Fresh weight tissue 
GAT   Glyphosate N-acetyltransferase 
GLP   Good Laboratory Practices 
Glufosinate- 
ammonium  Broad-spectrum systemic herbicide 
Glyphosate  Broad-spectrum systemic herbicide 
GM    Genetically modified 
GMO   Genetically modified organism 
GMP   Genetically modified plant 
H    hybrid 
ha    Hectare 
ILSI    International Life Sciences Institute 
IPM    Integrated Pest Management 
IRM    Insect resistance management 
Locus   The position that a given gene occupies on a chromosome 
LOD    Limit of detection 
LOQ    Limit of quantitation 
MALDI-TOF Matrix-Assisted Laser Desorption/Ionization-Time Of Flight. A mass 
spectrometry method used for detection and characterisation of biomolecules, 
such as proteins, peptides, oligosaccharides and oligonucleotides, with 
molecular masses between 400 and 350,000 Da 
MCB    Mediterranean corn borer, Sesamia nonagrioides 
mRNA   Messenger RNA 
MT   Norwegian Food Safety Authority (Mattilsynet) 
NDF  Neutral detergent fibre, measure of fibre used for animal feed analysis. NDF 
measures most of the structural components in plant cells (i.e. lignin, 
hemicellulose and cellulose), but not pectin 
Northern blot Northern blot is a technique used in molecular biology research to study gene 
expression by detection of RNA or isolated mRNA in a sample  
NTO    Non-target organism 
Nicosulfuron  Herbicide for maize that inhibits the activity of acetolactate synthase 
Near-isogenic lines  Term used in genetics, defined as lines of genetic codes that are identical 
except for differences at a few specific locations or genetic loci  
OECD   Organisation for Economic Co-operation and Development  
ORF Open Reading Frame, in molecular genetics defined as the part of a reading 
frame that contains no stop codons  
OSL    Overseason leaf 
OSR    Overseason root 
OSWP    Overseason whole plant 
pat Phosphinothricin-Acetyl-Transferase gene 
PAT Phosphinothricin-Acetyl-Transferase protein 
PCR Polymerase chain reaction, a biochemical technology in molecular biology to 
amplify a single or a few copies of a piece of DNA  
R0    Transformed parent 
Rimsulfuron  Herbicide, inhibits acetolactate synthase 
RNA  Ribonucleic acid 
RP    Recurrent parent 
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SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis. Technique to 
separate proteins according to their approximate size 
SAS    Statistical Analysis System 
SD    Standard deviation 
Southern blot Method used for detection of DNA sequences in DNA samples. Combines 
transfer of electrophoresis-separated DNA fragments to a filter membrane and 
subsequent fragment detection by probe hybridisation  
T-DNA Transfer DNA, the transferred DNA of the tumour-inducing (Ti) plasmid of 
some species of bacteria such as Agrobacterium tumefaciens and A. 
rhizogenes. The bacterium transfers this DNA fragment into the host plant's 
nuclear genome. The T-DNA is bordered by 25-base-pair repeats on each end. 
Transfer is initiated at the left border and terminated at the right border and 
requires the vir genes of the Ti plasmid. 
TI    Trait integration 
TMDI  Theoretical Maximum Daily Intake 
U.S. EPA  United States Environmental Protection Agency. 
 
Maize growth stages: Vegetative 
VE: emergence from soil surface 
V1: collar of the first leaf is visible 
V2: collar of the second leaf is visible  
Vn: collar of the leaf number 'n' is visible  
VT: last branch of the tassel is completely visible 
 
Reproductive 
R0: Anthesis or male flowering. Pollen shed begins 
   R1: Silks are visible 
R2: Blister stage, Kernels are filled with clear fluid and the embryo can be 
seen  
R3: Milk stage. Kernels are filled with a white, milky fluid.  
R4: Dough stage. Kernels are filled with a white paste  
R5: Dent stage. If the genotype is a dent type, the grains are dented 
R6: Physiological maturity 
 
Seedling growth (stages VE and V1); Vegetative growth (stages V2, V3... 
Vn); Flowering and fertilization (stages VT, R0, and R1); Grain filling and 
maturity (stages R2 to R6) 
 
Western blot  Analytical technique used to detect specific proteins in the given sample of 
tissue homogenate or extract. It uses gel electrophoresis to separate native 
proteins by 3-D structure or denatured proteins by the length of the 
polypeptide. The proteins are then transferred to a membrane where they are 
stained with antibodies specific to the target protein. 
WHO  World Health Organisation.  
ZM  Zea maize L. 
ZM-HRA A modified version of the native acetolactate synthase protein from maize. 
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On 19 September 2005, the European Food Safety Authority (EFSA) received from the Competent 
Authority of United Kingdom an application (Reference EFSA/GMO/UK/2005/20) for authorisation 
of the insect-resistant and herbicide tolerant genetically modified (GM) maize 59122 x NK603 
(Unique Identifier DAS-59122-7 x MONØØ6Ø3-6), submitted by Pioneer Hi-Bred International, Inc. 
within the framework of Regulation (EC) No 1829/2003.  
 
The scope of the application covers:  
• Food 
 GM plants for food use 
 Food containing or consisting of GM plants 
 Food produced from GM plants or containing ingredients produced from GM 
plants 
• Feed 
 GM plants for feed use 
 Feed containing or consisting of GM plants 
 Feed produced from GM plants 
 
• GM plants for environmental release 
 Import and processing (Part C of Directive 2001/18/EC) 
 
After receiving the application EFSA/GMO/NL/2005/20 and in accordance with Articles 5(2)(b) and 
17(2)b of Regulation (EC) No 1829/2003, EFSA informed the EU- and EFTA Member States (MS) 
and the European Commission and made the summary of the dossier publicity available on the EFSA 
website. EFSA initiated a formal review of the application to check compliance with the requirements 
laid down in Articles 5(3) and 17(3) of regulation (EC) No 1829/2003. On 20 June 2007, EFSA 
declared the application as valid in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 
1829/2003.  
 
EFSA made the valid application available to Member States and the EC and consulted nominated risk 
assessment bodies of the MS, including the Competent Authorities within the meaning of Directive 
2001/18/EC (EC 2001), following the requirements of Articles 6(4) and 18(4) of Regulation (EC) No 
1929/2003, to request their scientific opinion. Within three months following the date of validity, all 
MS could submit via the EFSA GMO Extranet to EFSA comments or questions on the valid 
application under assessment. The VKM GMO Panel assessed the application in connection with the 
EFSA official hearing, and submitted a preliminary opinion in September 2007 (VKM 2007a). EFSA 
published its scientific opinion 19 November 2008 (EFSA 2008), and maize stack 59122 x NK603 
was approved for food and feed uses, import and processing in 30 October 2009 (Commission 
Decision 2009/815/EC).  
 
An application for authorisation of maize 59122 x NK603 for cultivation in the EU was submitted by 
Pioneer Hi-Bred International, Inc. in January 2006 (EFSA/GMO/UK/2006/29). The application was, 
however, withdrawn by the notifier in December 2006.  
 
Scientific opinions on the parental lines of the stack 59122 x NK603 have previously been submitted 
by the VKM GMO Panel (VKM 2005a,b,d, 2008b). In addition, maize 59122 and NK603 have been 
evaluated by the VKM GMO Panel as a component of several stacked GM maize events under 
Directive 2001/18/EC and Regulation (EC) 1829/2003 (VKM 2005b, VKM 2007b,c, VKM 2008c, 
VKM 2009a,b, VKM 2012). 
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Terms of reference 
 
 
The Norwegian Environment Agency (former Norwegian Directorate for Nature Management) has the 
overall responsibility for processing applications for the deliberate release of genetically modified 
organisms (GMOs). This entails inter alia coordinating the approval process, and to make a holistic 
assessment and recommendation to the Ministry of the Environment regarding the final authorization 
process in Norway. The Directorate is responsible for assessing environmental risks on the deliberate 
release of GMOs, and to assess the product's impact on sustainability, benefit to society and ethics 
under the Gene Technology Act. 
 
The Norwegian Food Safety Authority (NFSA) is responsible for assessing risks to human and animal 
health on deliberate release of GMOs pursuant to the Gene Technology Act and the Food Safety Act. 
In addition, the NFSA administers the legislation for processed products derived from GMO and the 
impact assessment on Norwegian agriculture according to sector legislation. 
 
 
The Norwegian Environment Agency 
 
In preparation for a legal implementation of EU-regulation 1829/2003, the Norwegian Environment 
Agency, by letter dated 13 June 2012 (ref. 2008/4367/ART-BI-BRH), requests the Norwegian 
Scientific Committee for Food Safety, to conduct final environmental risk assessments for all 
genetically modified organisms (GMOs) and products containing or consisting of GMOs that are 
authorized in the European Union under Directive 2001/18/EC or Regulation 1829/2003/EC. The 
request covers scope(s) relevant to the Gene Technology Act. 
 
The request does not cover GMOs that the Committee already has conducted its final risk assessments 
on. However, the Norwegian Environment Agency requests the Committee to consider whether 
updates or other changes to earlier submitted assessments are necessary. 
 
The basis for evaluating the applicants’ environmental risk assessments is embodied in the Act 
Relating to the Production and Use of Genetically Modified Organisms etc. (the Norwegian Gene 
Technology Act), Regulations relating to impact assessment pursuant to the Gene Technology Act, the 
Directive 2001/18/EC on the deliberate release of genetically modified organisms into the 
environment, Guidance note in Annex II of the Directive 2001/18 (2002/623/EC) and the Regulation 
1829/2003/EC. In addition, the EFSA guidance documents on risk assessment of genetically modified 
plants and food and feed from the GM plants (EFSA 2010, 2011a), and OECD guidelines will be 
useful tools in the preparation of the Norwegian risk assessments. 
 
The risk assessments’ primary geographical focus should be Norway, and the risk assessments should 
include the potential environmental risks of the product(s) related to any changes in agricultural 
practices. The assignment covers assessment of direct environmental impact of the intended use of 
pesticides with the GMO under Norwegian conditions, as well as changes to agronomy and possible 
long-term changes in the use of pesticides. 
 
 
The Norwegian Food Safety Authority  
 
In preparation for a legal implementation of EU-regulation 1829/2003, the Norwegian Environment 
Agency has requested the Norwegian Food Safety Authority (NFSA) to give final opinions on all 
genetically modified organisms (GMOs) and products containing or consisting of GMOs that are 
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authorized in the European Union under Directive 2001/18/EC or Regulation 1829/2003/EC within the 
Authority’s sectoral responsibility. The request covers scope(s) relevant to the Gene Technology Act.  
 
The Norwegian Food Safety Authority has therefore, by letter dated 13 February 2013 (ref. 
2012/150202), requested the Norwegian Scientific Committee for Food Safety (VKM) to carry out 
final scientific risk assessments of 39 GMOs and products containing or consisting of GMOs that are 
authorized in the European Union.  
 
The assignment from NFSA includes food and feed safety assessments of genetically modified 
organisms and their derivatives, including processed non-germinating products, intended for use as or 
in food or feed.  
 
In the case of submissions regarding genetically modified plants (GMPs) that are relevant for 
cultivation in Norway, VKM is also requested to evaluate the potential risks of GMPs to the 
Norwegian agriculture and/or environment. Depending on the intended use of the GMP(s), the 
environmental risk assessment should be related to import, transport, refinement, processing and 
cultivation. If the submission seeks to approve the GMP(s) for cultivation, VKM is requested to 
evaluate the potential environmental risks of implementing the plant(s) in Norwegian agriculture 
compared to existing varieties (e.g. consequences of new genetic traits, altered use of pesticides and 
tillage). The assignment covers both direct and secondary effects of altered cultivating practices.  
 
VKM is further requested to assess risks concerning coexistence of cultivars. The assessment should 
cover potential gene flow from the GMP(s) to conventional and organic crops as well as to compatible 
wild relatives in semi-natural or natural habitats. The potential for establishment of volunteer 
populations within the agricultural production systems should also be considered. VKM is also 
requested to evaluate relevant segregation measures to secure coexistence during agricultural 
operations up to harvesting. Post-harvest operations, transport, storage are not included in the 
assignment.  
 
Evaluations of suggested measures for post-market environmental monitoring provided by the 
applicant, case-specific monitoring and general surveillance, are not covered by the assignment from 

















Maize 59122xNK603 has been obtained from traditional breeding methods between progeny (inbred 
lines) of the genetically modified maize lines 59122 and NK603.  
 
The parental line 59122 expresses the cry34Ab1 and cry34Ab1genes from Bacillus thuringiensis, 
conferring resistance to certain coleopteran target pests belonging to the genus Diabrotica, such as the 
larvae of western corn rootworm (D. virgifera virgifera), northern corn rootworm (D. barberi) and the 
southern corn rootworm (D. undecimpunctata howardi). Maize 59122 also expresses the PAT protein 
from S. viridochromogenes.  
 
The parental line NK603 is tolerant to glyphosate-based herbicides due to the expression of the CP4 
epsps gene from Agrobacterium sp. strain CP4 (CP4 EPSPS and CP4 EPSPS L214P, a variant of CP4 
EPSPS containing a proline residue at position 214 instead of leucine). 
 
None of the target pests for maize 59122 are present in the Norwegian agriculture. The PAT protein 
expressed in maize 59122 has been used as selectable markers to facilitate the selection process of 
transformed plant cells and is not intended for weed management purposes. 
 
Maize stack 59122xNK603 has been evaluated with reference to its intended uses in the European 
Economic Area (EEA), and according to the principles described in the Norwegian Food Act, the 
Norwegian Gene Technology Act and regulations relating to impact assessment pursuant to the Gene 
Technology Act, Directive 2001/18/EC on the deliberate release into the environment of genetically 
modified organisms, and Regulation (EC) No 1829/2003 on genetically modified food and feed.  
 
The Norwegian Scientific Committee for Food Safety has also decided to take account of the 
appropriate principles described in the EFSA guidelines for the risk assessment of GM plants and 
derived food and feed (EFSA 2011a), the environmental risk assessment of GM plants (EFSA 2010), 
the selection of comparators for the risk assessment of GM plants (EFSA 2011b), and for the post-
market environmental monitoring of GM plants (EFSA 2011c).  
 
The environmental risk assessment of the genetically modified maize 59122xNK603 is based on 
information provided by the applicant in the applications EFSA/GMO/UK/2005/20, and scientific 
opinions and comments from EFSA and other member states made available on the EFSA website 
GMO Extranet. The risk assessment is also based on a review and assessment of relevant peer-
reviewed scientific literature.  
 
It is emphasized that the VKM mandate does not include assessments of contribution to sustainable 
development, societal utility and ethical considerations, according to the Norwegian Gene Technology 
Act and Regulations relating to impact assessment pursuant to the Gene Technology Act. These 
considerations are therefore not part of the risk assessment provided by the VKM Panel on Genetically 
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2 Molecular characterisation 
 
2.1 Evaluation of relevant scientific data 
 
2.1.1 Method of production of maize 59122xNK603 
 
Conventional breeding methods were used to develop maize 59122xNK603. The three inserts present 
in maize 59122xNK603 were derived from two independent events: 59122 and NK603, and combines 
resistance to corn rootworm larvae (Coleoptera: Chrysomelidae; Diabrotica spp.) and tolerance to 
glufosinate-ammonium and glyphosate based herbicides.  
 
2.1.2 Summary of evaluation of the single events 
 
2.1.2.1 Maize 59122 
The gene modified maize strain 59122 expresses herbicide and insect tolerance through 
Agrobacterium tumefaciens mediated transformation of maize cells, with the insertion of a linear DNA 
fragment of 7390 bp from the binary vector PHP17662 into the maize genome. The DNA fragment 
does not contain an antibiotic resistance gene. Transformation of 59122 maize resulted in the stable 
insertion of the T-DNA region into the maize genome. The T-DNA region in PHP17662 contained the 
cry34Ab1, cry35Ab1 and pat coding sequences and the necessary regulatory components to regulate 
gene expression.  
 
The maize-optimised cry34Ab1 gene was derived from Bacillus thuringiensis strain PS149B1. 
Cry34Ab1 encodes a protein comprising 123 amino acids. The amino acid sequence of the Cry34Ab1 
protein (14 kDa) encoded by the maize-optimised cry34Ab1 gene is identical to the Cry34Ab1 protein 
(14 kDa) expressed in the bacteria. Expression of the maize-optimised cry34Ab1 gene is regulated by 
the ubiquitin promoter from Zea mays (ubi1ZM). Termination of transcription for the maize-optimised 
cry34Ab1 gene is controlled by the terminator sequence from the Solanum tuberosum proteinase 
inhibitor II gene (pinII).   
 
The maize-optimised cry35Ab1 gene was derived from Bacillus thuringiensis strain PS149B1. 
Cry35Ab1 encodes a protein comprising 383 amino acids. The amino acid sequence of the Cry35Ab1 
protein (44 kDa) encoded by the maize-optimised cry35Ab1 gene is identical to the Cry35Ab1 protein 
expressed by the bacteria. Expression of the maize-optimised cry35Ab1 gene is regulated by the 
promoter from the Triticum aestivum peroxidase gene and its native leader. Termination of 
transcription is controlled by the terminator sequence from Solanum tuberosum proteinase inhibitor II 
gene (pinII).  
 
The Cry34Ab1 and Cry35Ab1 proteins act together in conferring resistance against certain coleopteran 
insect pests, such as Diabrotica spp. which are important maize pests.  
Maize 59122 also express the phosphinothricin-N-acetyltransferase (PAT) protein from Streptomyces 
viridochromogenes (previously described). 
The level of the proteins Cry34Ab1, Cry35Ab1 and PAT were analysed by ELISA. Samples were 
collected from 11 different experimental fields in Chile, US and Canada in 2002/2003, and 3 and 6 in 
Europe in 2003 and 2004, respectively. Samples were collected at four different developmental stages. 
Cry34Ab1 and Cry35Ab1 was detected in leaves, pollen, seeds roots, stalk, and whole plants, whereas 
PAT was detected in leaves, roots, stalk and whole plant. The levels of PAT in seeds and pollen were 
below the detection limit. The expression of Cry34Ab1 and Cry35Ab1 varied between the different 
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tissues of the plants and between experimental fields. The concentration of Cry35Ab1 in pollen was 
either low or below detection levels, whereas the concentration of Cry34Ab1 varied between 50 and 
74 µg/g dw. In samples collected in Europe the concentrations of Cry34Ab1 and Cry35Ab1 in seeds 
were measured to be 61.8 ± 16.5 and 2.34 ± 0.475 µg/g dw, respectively, whereas samples from Chile 
and US/Canada showed 36.4 ± 8.9 og 2.0 ± 0.7 µg/g dw, respectively. The variation in protein 
concentration amongst samples collected from random blocks with and without herbicide treatment 
was shown to be higher than the variation between the experimental fields. The expression of PAT 
was generally low in all samples it was detected.  Results from whole plant extracts in Europe showed 
concentrations of 0.0807 ± 0.0800 µg/g dw. 
Western blot analysis and detection with polyclonal antibodies showed that the Cry34Ab1, Cry35Ab1 
and PAT proteins all had the expected molecular weights. Cry35Ab1 produced a double protein band, 
which was explained by proteolytic cleavage of a C-terminal fragment by plant proteases. No 
indications of fusion proteins were found. Studies performed to detect coding sequences in the maize 
strain 59122, did not disclose any ORFs that could lead to the expression of peptides larger than a 100 
amino acids.  
 
Southern blot and sequence analysis showed that nearly a full length copy of the PHP17662 
recombinant DNA fragment (7343 bp out of the 7390 bp fragment) is inserted in the maize genome. 
The 59122 maize does not contain fragments from the vector backbone portion of binary vector 
PHP17662, in particular the tetracycline and spectinomycin resistance genes, the virG gene and other 
backbone sequences not intended for transformation. In addition, PCR amplification and sequence 
analysis showed that the 5’ and 3’ regions flanking the 59122 maize insert are of maize genomic 
origin. A 22 bp are missing from the 5’ end and 25 bp from the 3’ end of the fragment. The fragment 
contains all genes (pat, cry34Ab1 and cry35Ab1) and respective regulatory sequences of the insert. 
Two base modifications have also been identified in the non-coding region of the fragment, but none 
of these affect the ORFs of the fragment. A 2593 bp of the 5’-, and 1986 bp of the 3’ - flanking 
sequences have also been sequenced, where small regions display homology to e.g. chromosomal 
sequences and various expressed sequence tags, ESTs. The longest region of these is 179 bp. None of 
the flanking sequences contain coding regions to known proteins. The contents of genes and 
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Figure 1.  Restriction map of the various gene elements of the recombinant DNA fragment inserted in the 
genome of the maize strain 59122. 
 
2.1.2.2 Maize NK603 
 
The maize line AW x CW, a proprietary maize cell culture, was transformed by acceleration to 
develop the NK603 maize event. Conventional breeding methods were used to backcross plants 
generated from the initial transformation into a recurrent, desired inbred maize line with a genetic 
background of interest to the breeder. 
 
NK603 has been developed for tolerance to glyphosate by the introduction of two genes coding for 
glyphosate tolerant 5-enoylpyruvylshikimate-3-phosphate synthase (EPSPS) from Agrobacterium sp. 
strain CP4 (CP4 EPSPS). Particle acceleration was used to introduce a fragment DNA from the 
bacterial plasmid vector PV-ZMGT32. The plasmid vector contains two adjacent plant gene 
expression cassettes each containing a single copy of the cp4 epsps gene fused to chloroplast transit 
peptide (CTP) sequences based on sequences derived from Arabidopsis thaliana EPSPS. CTP targets 
the CP4 EPSPS protein to its natural sub cellular location in the chloroplast. In the first ctp2-cp4 epsps 
cassette the coding sequence is regulated by the rice actin promoter and a rice intron sequence 
introduced upstream of the CTP sequence. Expression of the second ctp2-cp4 epsps cassette is 
regulated by an enhanced 35S CaMV promoter and a maize intron derived from a gene encoding a 
heat shock protein. In each cassette the cp4 epsps sequence is linked to the nopaline synthase 
terminator (NOS 3’) sequence from Agrobacterium tumefaciens. The vector also contains an nptII 
bacterial selectable marker gene (for kanamycin resistance; derived from the prokaryotic transposon 
Tn5) and an origin of replication (ori). A MluI restriction fragment of the PV-ZMGT32 plasmid 
vectoresignated PV-ZMGT32L was used for transformation and this fragment only contains the cp4 
epsps plant gene expression cassettes. The nptII gene as well as the ori is not present in the fragment 
PV-ZMGT32L. 
 
The EPSPS enzyme catalyzes the penultimate step of the shikimic acid pathway for the biosynthesis of 
aromatic amino acids, which is present in all green plants. Inhibition of this enzyme by glyphosate 
leads to a reduction of aromatic amino acids, interfering with plant growth, and ultimately leading to 
plant death. The herbicide Roundup has broad-spectrum weed control capabilities, but the sensitivity 
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of traditional maize to glyphosate had prevented the in-season use of this herbicide in the crop. With 
the expression of the glyphosate-tolerant CP4 EPSPS enzymes in NK603, the continued function of 
the aromatic amino acid pathway is ensured in the crop, even in the presence of the herbicide.  
 
The levels of CP4 EPSPS and CP4 EPSPS L214P proteins in various tissues of NK603, produced 
during the 1999 growing season in the E.U. and the 2002 growing season in the U.S.A. were estimated 
using an enzyme-linked immunosorbent assay (ELISA).  The expression of the CP4 EPSPS proteins 
occurs throughout the plant since the rice actin and CaMV e35S promoters have been shown to drive 
constitutive expression of the encoded protein in genetically modified maiz. As forage and grain are 
the most relevant tissues for the safety assessment, protein levels in these tissues were estimated in 
both growing seasons. Additionally, protein levels in pollen, forage root, OSL and OSR were 
estimated in the 2002 growing season. 
 
In 1999, forage and grain tissues were produced in European field trials at four sites. Four replications 
were used at each of the four sites. CP4 EPSPS protein levels were measured in maize forage and 
grain. All protein values are expressed as micrograms (µg) of the specific protein per gram (g) of 
tissue on a fresh weight (fw) basis.  Control maize samples were below the Limit of Detection (LOD) 
for CP4 EPSPS protein. In maize NK603 forage, the mean CP4 EPSPS protein levels from the four 
different field sites ranged from 43.6 µg/g fw to 60.9 µg/g fw. The overall mean CP4 EPSPS protein 
level in maize NK603 forage across all four sites was 48.6 µg/g fw. In maize NK603 grain, the mean 
CP4 EPSPS protein levels ranged from 2.2 µg/g fw to 13.2 µg/g fw. The overall mean CP4 EPSPS 
protein level in maize grain across all four sites was 8.4 µg/g fw. The values given represent the sum 
of both CP4 EPSPS and CP4 EPSPS L214P, as the ELISA analytical method recognizes both these 
proteins expressed in NK603.  
 
In 2002, test and control samples were produced in U.S.A. field trials. CP4 EPSPS protein levels in the 
different tissue types were estimated using a validated direct double antibody sandwich ELISA 
method. On a dry weight basis, the mean CP4 EPSPS protein levels across four field sites for 
overseason leaf tissues were 300-430 µg/g dw. The mean CP4 EPSPS protein levels across four field 
sites for overseason root tissues were 76-160 µg/g dw. The mean CP4 EPSPS protein levels across 
four field sites for forage, forage root, pollen, and grain tissues were 100, 140, 650, and 14 µg/g dw, 
respectively. The expression levels for forage and grain general agreement with the CP4 EPSPS levels 
measured in forage and grain samples collected from six non-replicated and two replicated field trials 
conducted in 1998 in the U.S.A. In the U.S.A. trials from 1998, CP4 EPSPS expression levels ranged 
from 18.0 to 31.2 µg/g fw for forage and from 6.9 to 15.6 µg/g fw for grain samples, respectively. 
 
Southern blot analysis was used to study the insert number, the copy number, the integrity of the 
inserted promoters, coding regions, and polyadenylation sequences, and the presence or absence of the 
plasmid backbone sequence. Polymerase chain reaction (PCR) was performed to verify the sequences 
at the 5’ and 3’ ends of the insert. Further, PCR analysis and subsequent DNA sequencing of four 
overlapping products spanning the length of the insert in NK603 were undertaken to characterize of 
the inserted DNA in NK603 (Kesterson et al., 2002a). Genomic DNA from the NK603 maize and 
control (B73) were digested with the restriction enzyme StuI. The result suggested that NK603 
contains one insertion of integrated DNA located within a 23 kb StuI restriction fragment. The genome 
of NK603 does not contain any detectable plasmid backbone DNA including ori or the nptII coding 
sequence. PCR amplification and DNA sequencing was used for characterization of the insert and the 
sequences flanking the insert. The results indicate that these sequences are native to the maize 
genome. These data indicate that only the expected full-length CTP2-CP4 EPSPS and CTP2-CP4 
EPSPS L214P proteins are encoded by the insert in NK603. The contents of genes and regulatory 
elements in the recombinant DNA fragment are outlined in Figure 2. 
 
 








Figure 2.  Restriction map of the various gene elements of the recombinant DNA fragment inserted in the 
genome of the maize strain NK603. 
 
 
2.1.3 Transgene constructs in 59122 x NK603 maize 
 
The 59122xNK603 maize was obtained by conventional crossing between two genetically modified 
oilseed rape events: 59122 and NK603 maize. No new genetic modification was used for the 
development of the 59122xNK603 maize.  
 
A detailed molecular analysis was conducted to investigate the copy number, structure and 
organization of the inserts found in 59122xNK603 maize. Genomic DNA was extracted from leaves 
harvested from 59122, NK603 and 59122xNK603 maize plants. The DNA samples were analyzed by 
the Southern blot method using different restriction enzymes and genetic probes specific for the 59122 
or NK603 maize inserts, respectively. Along with the 59122, NK603 and 59122xNK603 maize 
genomic DNA, positive control DNA was analyzed as well as negative control DNA containing 
genomic DNA from non-GM control maize with comparable genetic background to 59122xNK603 
maize. 
 
Samples of genomic DNA from four individual 59122xNK603 maize plants and from four individual 
59122 maize plants were digested with the restriction enzyme Sac I and subjected to Southern blot 
analysis with the cry34Ab1, cry35Ab1 and pat gene probes. Hybridization of the cry34Ab1 gene 
probe with the Sac I digested genomic DNA from 59122 maize was expected to result in a single right 
border fragment of more than 3217 bp. A single hybridization fragment of approximately 3400 bp was 
observed for both the 59122 and 59122 x NK603 maize genomic DNA.  
 
Sac I digestion of the 59122 maize genomic DNA and hybridization with the cry35Ab1 probe was 
expected to result in three internal hybridization fragments of 1941 bp, 1855 bp and 123 bp 
respectively. However, the predicted 123 bp fragment was not detected in the 59122 maize. The 
applicant concludes that fragments below approximately 1000 bp are run off the gel during 
electrophoresis and, therefore, are not transferred to the nylon membrane. The 1941 and 1855 bp 
hybridization fragments were observed for both the 59122 and 59122xNK603 maize genomic DNA 
using the cry35Ab1 gene probe in combination with Sac I digestion. The 1855 bp hybridization 
fragment for the pat gene probe was observed for both the 59122 and 59122 x NK603 maize genomic 
DNA. 
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In order to study the molecular equivalence and copy number of the insert present in NK603 maize to 
that present in 59122xNK603 maize, samples of genomic DNA from four individual 59122xNK603 
maize plants and from four individual NK603 maize plants were digested with the restriction enzyme 
EcoR V and subjected to Southern blot analysis with the cp4 epsps probe. Hybridization of the cp4 
epsps probe with the EcoR V digested NK603 maize genomic DNA was expected to result in two 
hybridization fragments of 3840 and 2818 bp respectively. Hybridization fragments of 3840 bp and 
2818 bp were observed for both the NK603 and 59122xNK603 maize genomic DNA.  
 
The results obtained from Southern Blot analyses indicate molecular equivalence, and identical copy 




2.1.3.1 Information on the expression of insert 
 
Two field studied was carried out in order to determine the level of the Cry34Ab1, Cry35Ab1, PAT 
and CP4 EPSPS proteins in grain obtained from 59122xNK603 maize. One field study was conducted 
during the 2003 growing season at six field sites, of which five were located in the USA and one was 
located in Canada (EFSA-GMO-UK-2005-20). Levels of the Cry34Ab1, Cry35Ab1, PAT and CP4 
EPSPS proteins in grain from 59122xNK603 maize were determined using a specific Enzyme Linked 
Immunosorbent Assay (ELISA) developed for each protein. Another field study was conducted during 
the 2004 growing season at five locations in Europe: three locations in Spain, one location in Bulgaria 
and one location in Hungary (EFSA-GMO-UK-2006-29). Levels of the Cry34Ab1, Cry35Ab1, PAT 
and CP4 EPSPS proteins in forage and grain from 59122xNK603 maize were determined using a 
specific Enzyme Linked Immunosorbent Assay (ELISA) developed for each protein. 
 
 
In the 2003 study, the 59122xNK603 maize grain samples were taken from plots that were sprayed 
with glyphosate herbicide only; from plots that were sprayed with glufosinate-ammonium herbicide 
only; and from plots sprayed with glyphosate herbicide followed by glufosinate-ammonium herbicide. 
The results obtained from the analysis have been summarised in Table 1. Levels of the Cry34Ab1, 
Cry35Ab1, PAT and CP4 EPSPS proteins in grain from 59122xNK603 maize were comparable 
regardless of the herbicide treatment (Table 1).  In the 2004 study, the 59122xNK603 maize forage 
and grain samples were taken from plots that were sprayed with two sequential applications of 
glyphosate herbicide; from plots that were sprayed with two sequential applications of glufosinate-
ammonium herbicide; and from plots sprayed with glyphosate herbicide followed by glufosinate-
ammonium herbicides. The results obtained from the analysis have been summarized in Table 2. 
Expression levels of the Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins in forage and grain 




In the 2003 study, the level of the Cry34Ab1 protein in grain from 59122xNK603 maize ranged from 
21.8 to 53.6 µg/g grain dry weight, while in the 2004 study the level ranged from 19.0 to 104 µg/g 
grain dry weight.  In 59122 maize grain, field trials in USA, Canada and Chile, the Cry34Ab1 level 
ranged from 19.5 to 84.8 µg/g grain dry weight. 
 
In the 2004 study, the level of the Cry34Ab1 protein in forage from 59122xNK603 maize ranged from 
85.8 to 138 µg/g forage dry weight. In forage from the 59122 maize the Cry34Ab1 level ranged from 
47.1 to 113 µg/g forage dry weight. 
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Cry35Ab1: 
In the 2003 study, the level of the Cry35Ab1 protein in grain from 59122xNK603 maize ranged from 
0.530 to 3.31 µg/g grain dry weight, while in the 2004 study the level ranged from 0.450 to 3.72 µg/g 
grain dry weight. In 59122 maize grain, field trials in USA, Canada and Chile, the Cry35Ab1 
expression level ranged from 0.48 to 4.8 µg/g grain dry weight. 
 
In the 2004 study , the level of the Cry35Ab1 protein in forage from 59122 x NK603 maize ranged 
from 22.8 to 49.2 µg/g forage dry weight. In forage from the 59122 maize the Cry35Ab1 level ranged 
from 15.8 to 76.6 µg/g forage dry weight. 
 
PAT: 
In the 2003 study, the level of the PAT protein in grain from 59122xNK603 maize ranged from below 
the lower limit of quantitation of the assay, which was 0.068 µg/g grain dry weight, to 0.440 µg/g 
grain dry weight, while in the 2004 study the level was below the lower limit of quantitation of the 
assay, which was 0.068 µg/g grain dry weight. In 59122 maize grain, field trials in USA, Canada and 
Chile, the PAT expression level ranged from below the lower limit of quantification of the PAT 
ELISA assay used to 0.94 µg/g grain dry weight. .  
 
In the 2004 study, the level of the PAT protein in forage from 59122 x NK603 maize ranged from 0.77 
to 4.14 µg/g forage dry weight. In forage from the 59122 maize the PAT expression level ranged from 





In the 2003 study, the level of the CP4 EPSPS protein in grain from 59122xNK603 maize ranged from 
3.06 to 16.4 µg/g grain dry weight, while in the 2004 study, the level ranged from 0.940 to 8.43 µg/g 
grain dry weight.  
 
In terms of µg/g fresh weight, the level of the CP4 EPSPS protein in grain from 59122xNK603 maize 
seems to be comparable to the CP4 EPSPS protein in grain from NK603maize. The level of the CP4 
EPSPS protein in 59122 x NK603 maize grain ranged from 2.601 to 13.94 µg/g fresh weight, while in 
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Table 1.  Protein expression level of the Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins in grain 
 from 59122 x NK603 maize plants sprayed with glyphosate; sprayed with glufosinate-ammonium; 













Table 2. Protein expression level of the Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins in forage and 
 grain from 59122 x NK603 maize plants sprayed with two sequential applications of glyphosate 
 herbicide; sprayed with two sequential applications of glufosinateammonium herbicide; or 
 sprayed with glyphosate followed by glufosinate-ammonium herbicides (Europe locations, 2004) 
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2.1.3.2 Parts of the plant where the insert is expressed 
According to the applicant, the Cry34Ab1, Cry35Ab1 and CP4 EPSPS proteins are expressed in the 
leaf, root, pollen, stalk and grain of the 59122xNK603 maize. The PAT protein is expressed in the 
leaf, root and stalk of the 59122xNK603 maize. The level of the PAT protein in 59122xNK603 maize 
grain and pollen was below the lower limit of quantitation of the assay used. In addition, according to 
the applicant, the levels of the Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins in the different 
tissues of 59122xNK603 maize were comparable regardless of herbicide treatment. 
 
2.1.3.3 Potential fusion proteins 
Southern Blot analyses conducted on 59122xNK603 maize indicate molecular equivalence and 
identical copy number of the inserts present in 59122xNK603 maize to those present in 59122 and 
NK603 maize, respectively.  
 
2.1.3.4 Inheritance and genetic stability of inserted DNA 
 
According to the data from the applicant, the parental maize lines 59122 and NK603 have both 
incorporated a single DNA insert containing a single copy of their respective DNA fragments, and that 
these are located at different loci in the maize genome. Interactions of the transgene inserts are 
therefore expected to be minimal during conventional breeding of the genetically modified maize lines 
59122 and NK603.  
 
Southern blot analyses, carried out on 83 individual plants from a single 59122xNK603 maize 
generation, indicate that the integrity of the inserts in the single events in 59122 and NK603 maize are 
preserved in the hybrid 59122 x NK603. Furthermore, protein expression levels, phenotypic 
characteristics and agronomic performance, indicate that the integrity of the inserts inherited from the 





Southern and PCR analyses indicate that the recombinant inserts in the single maize events 59122 and 
NK603 are retained in maize stack 59122xNK603. Genetic stability of the inserts has previously been 
demonstrated in the parental lines 59122 and NK603. The level of Cry34Ab1/Cry35Ab1, PAT and 
CP4 EPSPS proteins in seed and forage from the stacked event are comparable to the levels in the 
single events. Phenotypic analyses also indicate stability of the insect resistance and herbicide 
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3 Comparative assessment 
 
3.1 Choice of comparator and production of material for the 
compositional assessment 
 
3.1.1 Experimental design & statistical analysis 
 
In the application EFSA/GMO/UK/2005/20 for food and feed uses, import and processing of maize 
59122xNK603 within the European Union, the applicant present compositional data from seed and 
forage material collected in field trials in the North America during the 2003 growth season. In 
addition, data derived from material obtained from field trials with the single events and the respective 
comparators were provided by the applicant.  
 
The field trials were performed at five separate sites in commercial maize-growing regions of the USA 
(Iowa, Indiana and Nebraska) and one field site in Ontario, Canada. These trials compared the 
composition of maize 59122xNK603 with a conventional counterpart having a genetic background 
representative of the test entry 59122 x NK603. The test of equivalence is used to verify whether the 
agronomic, phenotypic and compositional characteristics of the GM plant fall within the normal range 
of natural variation. Such a range of natural variation is estimated from a set of non-GM reference 
varieties with a history of safe use (EFSA 2010b) and therefore allows comparisons of the GM plant 
with a similar food or feed produced without the help of genetic modification and for which there is a 
well-established history of safe use. In this application, comparisons with baseline data on commercial 
maize, compiled from publicly available literature, have been used in the comparisons with maize 
59122xNK603 for considerations of natural variations. 
 
At each trial site, maize 59122xNK603 and the conventional counterpart were planted following a 
randomized complete block design containing four blocks with test and control entries planted in 2-
row plots located randomly within each block. Each plot was bordered by a single row of non-
transgenic, commercial maize in order to limit edge effects. Prior to planting, each site prepared a 
proper seed bed according to local agronomic practices which could include tillage, fertility and pest 
managements practices. Each field location was scouted for agronomic and pest management needs 
including pest arthropods, diseases and weeds. Fertilizer, irrigation, agricultural chemicals and other 
management practices were applied as necessary. All maintenance operations were performed 
uniformly across the entire study area.  
 
Three of the blocks were used in the comparative assessment and the additional block was used for 
obtaining samples for protein expression analysis. 59122xNK603 maize grown for compositional 
analysis either received two applications of glyphosate, two applications of glufosinate-ammonium, or 
one application of glyphosate followed by one application of glufosinate-ammonium. Maize 59122 x 
NK603 grown for agronomic analysis received one application of glyphosate followed by one 
application of glufosinate-ammonium. Plots untreated with the target herbicides were not included in 
the field study. 
 
Two separate statistical analyses were carried out on the composition data. For the first analysis, the 
data from all replicates and all locations were combined and analyzed. Least-square means and 
standard deviation were calculated for the data across all six locations and statistically significant 
differences were identified using a t-test at a 5% level of significance. 
 
For the second statistical analysis, the results obtained were evaluated on a per location basis using 
data from the 3 replicates of each maize entry at each location. The least-square means and standard 
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deviation for each location and maize entry were calculated and statistically significant differences 
were identified using a t-test at a 5% level of significance. 
 
 
3.2 Compositional Analysis 
 
The nutritional analysis was undertaken on a broad range of compounds in grain from 59122xNK603 
maize in accordance with OECD guidelines for assessment of GM maize (OECD, 2002). The 
objective was to determine that 59122xNK603 maize treated with glyphosate, glufosinate-ammonium, 
or glyphosate followed by glufosinate-ammonium herbicides, was equivalent to non-GM control 
maize with comparable genetic background. Grain samples from 59122xNK603 maize (all herbicide 
treatments) and non-GM control maize with comparable genetic background were collected and 
analyzed for nutrient composition, including: crude protein, crude fat, crude fiber, acid detergent fiber 
(ADF), neutral detergent fiber (NDF), ash, carbohydrates, fatty acids (palmitic, stearic, oleic, linoleic, 
and linolenic acids), amino acids (methionine, cystine, lysine, tryptophan, threonine, isoleucine, 
histidine, valine, leucine, arginine, phenylalanine, glycine, alanine, aspartic acid, glutamic acid, 
proline, serine, and tyrosine), minerals (phosphorus, calcium, copper, iron, magnesium, manganese, 
potassium, sodium, zinc) vitamins (beta-carotene, vitamin B1, vitamin B2, folic acid, and vitamin E 
[alpha tocopherol isomer]), secondary metabolites (inositol, furfural, p-coumaric acid and ferulic 
acid), and anti-nutrients (phytic acid, raffinose and trypsin inhibitor).  
 
Compositional analysis of maize forage included the determination of proximates (crude protein, 
crude fat, ash), crude fiber, acid detergent fiber (ADF), natural detergent fiber (NDF), carbohydrates 
and minerals (calcium and phosphorus). 
 
According to the applicant, and in accordance with OECD guidelines (OECD, 2002), substantial 
equivalence was evaluated by comparing the mean nutrient composition values of each 59122xNK603 
maize entry to non-GM maize with comparable genetic background, and mean nutrient composition 
values of the 59122xNK603 maize entry to nutrient ranges available in the published literature. 
Statistical analyses were conducted with data combined across all six locations as well as on a per 
location basis using data from the 3 replicates at each of the individual locations. 
 
Forage: 
Proximates and fiber: 
No statistically significant differences were observed for mean crude fat, crude fiber, ADF, NDF, or 
ash in the across location summary analysis. Mean crude protein and carbohydrates values across 
locations in the 59122xNK603 + glyphosate hybrid were significant different (P<0.05) (Table 1 – 
appendix). Significant differences for crude protein were only observed at two of six locations. 
Significant differences for carbohydrates were only observed at one of the six locations. The across 
locations mean values for all forage proximate, fiber and carbohydrate analytes for test and control 
hybrids were within reported literature ranges (Table 3 – appendix). 
 
Minerals: 
Mean calcium and phosphorus values across locations in the 59122xNK603 + glyphosate hybrid were 
significant different (P<0.05) (Table 2 – appendix). No statistically significant differences for calcium 
were observed at any of the individual locations. Statistically significant differences for phosphorus 
were only observed at two of the six locations. The mean values for calcium and phosphorus for the 
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Grain: 
Proximates and fibers: 
No statistically significant (P<0.05) differences were observed across locations between 
59122xNK603 maize treated with glyphosate and non-GM control maize with regard to crude fiber or 
NDF values. Statistically significant differences were observed for crude protein, crude fat, ADF, ash 
and carbohydrates in the analysis across locations (Table 4 – appendix). However, when analyzed on a 
per location basis, these differences were not consistently observed. No statistically significant 
differences were observed between 59122 x NK603 and the non-GM control maize for crude fat and 
ADF at any of the six individual locations. With regard to crude protein and ash, no statistically 
significant differences were observed at three out of the six individual locations. With regard to 
carbohydrates, no statistically significant differences were observed at two out of the six individual 
locations.  
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glufosinate and non-GM control maize with regard to ADF, crude fiber or NDF. 
Statistically significant differences were observed for crude protein, crude fat, ash and carbohydrates 
in the analysis across locations (Table 5 – appendix)). However, when analyzed on a per location 
basis, these differences were not consistently observed. No statistically significant differences were 
observed at five out of the six individual locations for crude fat. No statistically significant differences 
were observed at three out of the six individual locations for ash. No statistically significant 
differences were observed at one of the six individual locations for crude protein and carbohydrates 
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate followed by glufosinate and non-GM control maize with regard to crude fat or 
crude fiber. Statistically significant differences between 59122 x NK603 maize and non-GM control 
maize were observed for crude protein, ADF, NDF, ash and carbohydrates (Table 6 – appendix). 
However, when analysed on a per location basis, these differences were not consistently observed. No 
statistically significant differences were observed at five out of the six individual locations for ADF 
and NDF. No statistically significant differences were observed at two out of the six individual 
locations for crude protein and ash. No statistically significant differences were observed at one out of 
the six locations for carbohydrates. In addition, all mean values for proximates, fiber and 
carbohydrates in grain from 59122 x NK603 maize treated with glyphosate followed by glufosinate 
and in grain from non-GM control maize were within reported literature ranges (Table 7 – appendix)). 
 
Fatty acids: 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate and non-GM control maize with regard to linolenic acid. Statistically 
significant differences were observed for palmitic acid, stearic acid, oleic acid and linolenic acid in the 
analysis across locations (Table 8 - appendix). However, when analyzed on a per location basis, these 
differences were not consistently observed. No statistically significant differences were observed for 
palmitic acid and stearic acid at four out of the six individual locations. With regard to oleic and 
linoleic acid, the mean values obtained from the analysis on a per location basis were not statistically 
different from the control at two out of the six individual locations.  
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glufosinate and non-GM control maize with regard to linolenic acid. Statistically 
significant differences were observed for palmitic acid, stearic acid, oleic acid and linoleic acid in the 
analysis across locations (Table 9 - appendix). However, when analyzed on a per location basis, these 
differences were not consistently observed. No statistically significant differences were observed for 
palmitic acid at any of the six individual locations. No statistically significant differences were 
observed for stearic acid at four out of the six individual locations. No statistically significant 
differences were observed for oleic and linoleic acid at two out of the six individual locations.  
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No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate followed by glufosinate and non-GM control maize with regard to linolenic 
acid. Statistically significant differences between 59122 x NK603 maize and non-GM control maize 
were observed for palmitic acid, stearic acid, oleic acid and linoleic acid in the analysis across 
locations (Table 10 - appendix). However, when analysed on a per location basis no statistically 
significant differences between 59122 x NK603 maize and non-GM control maize were observed at 
five out of six individual locations for palmitic acid. No statistically significant differences were 
observed at four and three out of the six individual locations for stearic and oleic acid respectively. 
Statistically significant differences for linoleic acid were observed at six locations. However, 
statistically significant differences for linoleic acid were not consistently observed across locations for 
grain from 59122 x NK603 maize treated with glyphosate, nor for grain from 59122 x NK603 maize 
treated with glufosinate, indicating the absence of an obvious trend. Furthermore, all mean values for 
fatty acids in grain from 59122 x NK603 maize treated with glyphosate followed by glufosinate and in 
grain from non-GM control maize were within reported literature ranges (Table 11 – appendix). 
 
Amino acids: 
Statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate and non-GM control maize with regard to methionine, cystine, lysine, 
tryptophan, threonine, isoleucine, histidine, valine, leucine, arginine, phenylalanine, glycine, alanine, 
aspartic acid, glutamic acid, proline, serine or tyrosine (Table 12 - appendix). However, when 
analyzed on a per location basis, these differences were not consistently observed. No statistically 
significant differences were observed at any of the six individual locations for methionine and cystine. 
No statistically significant differences were observed on a per location basis for five out of the six 
individual locations for lysine, glycine and tyrosine. No statistically significant differences were 
observed on a per location basis for four out of the six individual locations for tryptophan, threonine, 
aspartic acid and serine. No statistically significant differences were observed on a per location basis 
for three out of the six individual locations for isoleucine, histidine, valine, leucine, arginine, 
phenylalanine, glutamic acid and proline. No statistically significant differences were observed on a 
per location basis for two out of the six individual locations for alanine. In addition, all mean values 
for amino acids in grain from 59122 x NK603 maize treated with glyphosate and in grain from non-
GM control maize were within reported literature ranges.  
 
Statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glufosinate and non-GM control maize with regard to methionine, cystine, lysine, 
tryptophan, threonine, isoleucine, histidine, valine, leucine, arginine, phenylalanine, glycine, alanine, 
aspartic acid, glutamic acid, proline, serine and tyrosine (Table 13 - appendix). However, when 
analyzed on a per location basis, these differences were not consistently observed. No statistically 
significant differences were observed at five out of the six individual locations for lysine and glycine. 
No statistically significant differences were observed on a per location basis for four out of the six 
individual locations for methionine, cystine, tryptophan, threonine, histidine, valine, aspartic acid, 
glutamic acid, proline, serine and tyrosine. No statistically significant differences were observed on a 
per location basis for three out of the six individual locations for isoleucine, leucine and alanine. No 
statistically significant differences were observed on a per location basis for two out of the six 
individual locations for arginine and phenylalanine.  
Statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate followed by glufosinate and non-GM control maize with regard to methionine, 
cystine, lysine, tryptophan, threonine, isoleucine, histidine, valine, leucine, arginine, phenylalanine, 
glycine, alanine, aspartic acid, glutamic acid, proline, serine or tyrosine (Table 14 - appendix). 
However, when analysed on a per location basis, these differences were not consistently observed. No 
statistically significant differences were observed at any of the six individual locations for lysine. No 
statistically significant differences were observed on a per location basis at five out of the six 
individual locations for cystine. No statistically significant differences were observed on a per location 
basis at four out of the six individual locations for methionine, tryptophan, threonine, histidine, 
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aspartic acid, proline, serine and tyrosine. No statistically significant differences were observed on a 
per location basis for three out of the six individual locations for isoleucine, phenylalanine, glycine, 
alanine and glutamic acid. No statistically significant differences were observed on a per location basis 
for two out of the six individual locations for valine and leucine. No statistically significant differences 
were observed on a per location basis at one out of the six individual locations for arginine. In 
addition, all mean values for amino acids in grain from 59122 x NK603 maize treated with glyphosate 
followed by glufosinate and in grain from non-GM control maize were within reported literature 
ranges (Table 15 - appendix). 
 
Minerals: 
Statistically significant differences between 59122 x NK603 maize treated with glyphosate and non-
GM control maize were observed for magnesium, manganese, phosphorus and potassium in the 
analysis across locations. No statistically significant differences were observed across locations for 
calcium, copper, iron, sodium or zinc (Table 16 - appendix). However, when analyzed on a per 
location basis, these differences were not consistently observed. No statistically significant differences 
were observed between 59122 x NK603 maize and non-GM control maize for magnesium at five of 
the six individual locations. No statistically significant differences were observed between 59122 x 
NK603 maize and non-GM control maize for manganese and potassium at four of the six individual 
locations. With regard to phosphorus, the mean values obtained from the analysis on a per location 
basis were not significantly different from non-GM control maize at three of the six locations.  
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glufosinate and non-GM control maize with regard to calcium, copper, iron, sodium or 
zinc. Statistically significant differences were observed for magnesium, manganese, phosphorus and 
potassium in the analysis across locations (Table 17 - appendix). However, when analyzed on a per 
location basis, these differences were not consistently observed. No statistically significant differences 
were observed at three of the six individual locations for magnesium, manganese and potassium. No 
statistically significant differences were observed at two of the six individual locations for phosphorus.  
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate followed by glufosinate and non-GM control maize with regard to calcium, 
copper, sodium or zinc. Statistically significant differences were observed for iron, magnesium, 
manganese, phosphorus and potassium in the analysis across locations (Table 18 - appendix). 
However, when analyzed on a per location basis, these differences were not consistently observed. No 
statistically significant differences were observed at any of the six individual locations for iron. No 
statistically significant differences were observed at four out of the six individual locations for 
magnesium, manganese and potassium. No statistically significant differences were observed at one 
out of the six individual locations for phosphorus. In addition, all mean values for minerals in grain 
from 59122 x NK603 maize treated with glyphosate followed by glufosinate and in grain from non-
GM control maize were within the reported literature ranges (Table 19 - appendix). 
 
Vitamins: 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate and non-GM control maize with regard to vitamin B1, folic acid or vitamin E. 
Levels of vitamin B2 in both the 59122 x NK603 maize grain and non- GM control maize grain were 
below the lower limit of quantitation (LLOQ) of the assay used in this analysis (Table 20 - appendix). 
Statistically significant differences were observed for beta-carotene. However for beta-carotene, the 
values obtained from the analysis on a per location basis were not statistically different between 59122 
x NK603 maize and the non-GM control maize at two out of the six individual locations.  
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glufosinate and non-GM control maize with regard to vitamin B1, folic acid and vitamin 
E. Levels of vitamin B2 for both the 59122 x NK603 maize grain and non- GM control maize grain 
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were below the LLOQ for the assay used in this analysis. Statistically significant differences were 
observed between 59122 x NK603 maize and non-GM control maize for beta-carotene in the analysis 
across locations (Table 21 - appendix). However, when analyzed on a per location basis, these 
differences were not consistently observed. No statistically significant differences were observed at 
two out of the six individual locations for beta-carotene values.  
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate followed by glufosinate and non-GM control maize with regard to folic acid 
and vitamin E. Levels of vitamin B2 for both the 59122 x NK603 maize grain and non-GM control 
maize grain were below the LLOQ for the assay used in this analysis. Statistically significant 
differences were observed between 59122 x NK603 maize and non-GM control maize for beta-
carotene and vitamin B1 in the analysis across locations (Table 22 - appendix). However, when 
analyzed on a per location basis, these differences were not consistently observed. No statistically 
significant differences were observed at five out of the six individual locations for vitamin B1 and no 
statistically significant differences were observed at four out of the six individual locations for beta-
carotene. In addition, all mean values for vitamins in 59122 x NK603 maize and non-GM control 
maize were within reported literature ranges with the exception of vitamin B1 values that for both the 
59122 x NK603 maize grain and the non-GM control maize grain were above the reported literature 
range (Table 23 - appendix). 
 
Secondary metabolites and anti-nutrients: 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate and non-GM control maize with regard to ferulic acid and trypsin inhibitor. 
Levels of furfural in both 59122 x NK603 maize treated with glyphosate and non-GM control maize 
were below the LLOQ of the assay used in this analysis (Table 24 and 28 - appendix). Statistically 
significant differences were observed for inositol, p-coumaric acid, raffinose and phytic acid (Table 24 
and 28 - appendix). However, when analyzed on a per location basis, no statistically significant 
differences were observed at any of the six individual locations for p-coumaric acid. No statistically 
significant differences were observed at four out of the six individual locations for inositol and 
raffinose. No statistically significant differences were observed at three out of the six individual 
locations for phytic acid.  
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glufosinate and non-GM control maize with regard to inositol, p-coumaric acid or ferulic 
acid. Levels of furfural in both 59122 x NK603 maize grain treated with glufosinate and non- GM 
control maize grain were below the LLOQ of the assay used in this analysis (Table 25 - appendix). 
Statistically significant differences between 59122 x NK603 maize and non-GM control maize were 
observed for raffinose, phytic acid and trypsin inhibitor in the analysis across locations (Table 29 - 
appendix). However, when analyzed on a per location basis, these differences were not consistently 
observed. No statistically significant differences were observed at five out of the six individual 
locations for raffinose and trypsin inhibitor and no statistically significant differences were observed at 
three out of the six individual locations for phytic acid.  
 
No statistically significant differences were observed across locations between 59122 x NK603 maize 
treated with glyphosate followed by glufosinate and non-GM control maize with regard to inositol, p-
coumaric acid, ferulic acid or trypsin inhibitor. Levels of furfural in both 59122 x NK603 maize grain 
and non-GM control maize grain were below the LLOQ of the assay used in this analysis (Table 26 
and 30 - appendix). Statistically significant differences between 59122 x NK603 maize treated with 
glyphosate followed by glufosinate and non- GM control maize were observed for raffinose and phytic 
acid in the analysis across locations. However, when analyzed on a per location basis, these 
differences were not consistently observed. No statistically significant differences were observed at 
any of the six individual locations for raffinose. No statistically significant differences were observed 
at five out of the six individual locations for phytic acid. In addition, all mean values for secondary 
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metabolites and anti-nutrients in grain from 59122 x NK603 maize treated with glyphosate followed 
by glufosinate and in grain from non-GM control maize were within reported literature ranges (Table 
27 and 31 -appendix). 
 
 
3.3 Agronomic and phenotypic characters  
 
During field trials over at six different locations in North America in the growth season 2003, 
phenotypic and agronomic data related to dormancy and germination, emergence and vegetative 
growth, reproductive growth, seed retention, and stress (i.e., disease and biotic stress responses) were 
collected. Both in the field trials in USA and Canada, the early population/germination, seeding 
vigour, time to silking, time to pollen shed, stay green, plant height, ear height, number of stalk and 
root lodged plants, final stand count, pollen shape and colour, disease incidence and insect damage, 
were measured. Yield/grain yield was not measured in these trials. 
 
Analyses of variance across trial locations showed statistically significant differences between maize 
59122 x NK603 (treated with glyphosate and glufosinate ammonium) and the corresponding 
conventional counterpart for mean time to silking, time to pollen shed and plant height (p<0.05) 
(Table 32 - appendix). On average, maize 59122 x NK603 plants were taller than the conventional 
counterpart (95 vs. 91 cm) and had higher number of accumulated heat units before 50 % of the plants 
were silking and shedding pollen (1242 vs. 1226 GDU, and 1277 vs. 1260 GDU) compared with the 
conventional counterpart. However, significant differences for these parameters were only observed at 
one of the test locations. No statistically significant differences between the transgenic maize 59122 x 
NK603 and the comparator were detected for any of the other assessed phenotypic characteristics in 





Comparative analyses of data from field trials located at representative sites and environments in the 
USA and Europe indicate that maize stack 59122 x NK603 is compositionally, agronomically and 
phenotypically equivalent to its conventional counterpart, with the exception of the herbicide 
tolerance, conferred by the expression of Cry34Ab1/Cry35Ab1, PAT and CP4 EPSPS proteins. Based 
on the assessment of available data, the VKM GMO Panel is of the opinion that conventional crossing 
of maize 59122 and NK603 to produce the hybrid 59122 x NK603 does not result in interactions that 
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4 Food /feed risk assessment 
 
4.1 Product description and intended uses 
 
According to the applicant, all 59122xNK603 maize products will be produced and processed for use 
in food, animal feed and industrial products in the same way as other commercial maize. The 
59122xNK603 maize and all food, feed and processed products derived from 59122xNK603 maize are 
expected to replace a portion of similar products from commercial maize, with total consumption of 
maize products remaining unchanged. Therefore, the applicant concludes that, the total anticipated 
intake/extent of use of maize and all food, feed and processed products derived from maize will 
remain the same. 
 
4.2 Effects of processing 
 
Food manufacturing includes many harsh processing steps, e.g. cooking, heating, high pressures, pH 
treatments, physical shearing, extrusion at high temperatures etc. under which the majority of both 
DNA and proteins are denatured, which also applies to Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS 
proteins (Hammond et al. 2011). 
 
 
4.3 Toxicological assessment 
  
4.3.1  Toxicological assessment of the newly expressed protein 
 
4.3.1.1 Acute oral toxicity testing 
 
Acute intravenous exposure of PAT protein in rodents  
Bayer Crop Sciences has performed an acute toxicity study of the PAT-protein in rats by a single 
intravenous administration. The study was performed in accordance with the principles of Good 
Laboratory of O.E.C.D. (Organization for Economic Cooperation and Development) Principles of 
Good Laboratory Practice, 1997,  European Commission Directive 1999/1 I/EC, 1999,  French decree 
n°98-1312, regarding Good Laboratory Practice, December 31, 1998, - E.P.A. (Environmental 
Protection Agency) • 40 CFR part 160 Federal Insecticide, Fungicide and Rodenticide Act (F1FRA): 
Good Laboratory Practice Standards: Final Rule, August 17, 1989, and Good Laboratory Practice 
Standards for Toxicology studies on Agricultural Chemicals, Ministry of Agriculture, Forestry and 
Fisheries (M.A.F.F.), notification 12 NohSan n°8628, (December 06 2000). 
 
The objective of this study was to assess the acute intravenous toxicity in OF1 mice of PAT 
(phosphoacetyl transferase) protein (> 95% purity), a protein encoded by the pat gene. In addition, the 
acute intravenous toxicity of aprotinin (negative control) and melittin (positive control) were also 
compared. Groups of 5 female OF1 mice were administered either with PAT protein, aprotinin or 
melittin in physiological saline at dose levels of 1 and 10 mg/kg body weight. 
 
All animals were observed for clinical signs daily for fifteen days whilst their body weights were 
measured weekly. No clinical signs were noted in PAT protein-treated animals or in control groups 
throughout the study period. The body weight evolution was unaffected by the treatment with either 
PAT protein at 1 and 10 mg/kg or control substances up to Day 15. At termination of the study period, 
animals were subjected to a necropsy including macroscopic examination. No treatment-related 
macroscopic abnormalities were detected in animals treated with either PAT protein at 1 and 10 mg/kg 
or control substances.The positive control (melittin), at 10 mg/kg, induced 100% mortality. Animals 
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treated at 1 mg/kg of melittin and negative control animals treated with aprotinin at 1 and 10 mg/kg 
showed no visible signs of systemic toxicity (Hèrouet et al. 2005). 
 
PAT Microbial Protein (FL), which was 84% pure microbial protein, was evaluated for acute oral 
toxicity. Five male and five female CD-1 mice received 6000 mg/kg of the test material (containing 
approximately 5000 mg/kg PAT) as a 25% w/v suspension in aqueous 0,5% methylcellulose. Because 
the volume of the test material in methylcellulose exceeded 2 ml/100g body weight, the test material 
suspension was administrated as two fractional gavage doses, given approximately one hour apart. 
Parameters evaluated during the two-week observation period included body weights and detailed 
clinical observation. All animals were examined for gross pathological changes. All mice survived to 
the end of the two-week observation period. There were no treatment-related clinical observation. All 
mice except one female gained weight over the duration of the study. There were no gross 
pathological   lesions for any animal on study. Under the condition of this study, the acute oral LD50 of 
PAT Microbial protein (FL) in male and female CD-1 mice was greater than 6000 mg/kg (Brooks and 
DeWildt, 2000). 
 
Acute oral exposure of Cry34Ab1 and Cry34Ab2 proteins in rodents 
The potential toxicity of the Cry34Ab1 and Cry35Ab1 proteins to humans and animals was examined 
in acute oral toxicology studies. The equivalent microbially-derived Cry34Ab1 and Cry35Ab1 
proteins were evaluated either separately or as a Cry34Ab1/Cry35Ab1 protein mixture for acute 
toxicity potential in mice (Brooks and DeWildt 2000a; Brooks and DeWildt 2000b; Brooks and 
DeWildt 2000c).  
 
The Cry34Ab1 protein was evaluated for acute oral toxicity and the highest dose tested was 5000 mg 
of test material per kg body weight. When adjusted for purity of the test material (54% pure; Brooks 
and DeWildt 2000a), the dose was 2700 mg Cry34Ab1 protein per kg body weight. During the two-
week observation period, mortality and/or clinical or behavioural signs of pathology as well as body 
weights were recorded. Gross necropsies were conducted at the end of the study. No mortality 
occurred during the course of the study. Additionally, no adverse clinical signs were observed during 
the study and no adverse findings were noted at necropsy. The relatively high dose tested in this study 
did not give rise to any toxicity and therefore the acute LD50 for Cry34Ab1 protein could not be 
determined and is estimated to be higher than 2700 mg Cry34Ab1 per kg body weight.  
 
The Cry35Ab1 protein was evaluated for acute oral toxicity and the highest dose tested was 5000 mg 
of test material per kg body weight. When adjusted for purity of the test material (37% pure; Brooks 
and DeWildt 2000b), the dose was 1850 mg Cry35Ab1 protein per kg body weight. During the two-
week observation period, mortality and/or clinical or behavioural signs of pathology as well as body 
weights were recorded. Gross necropsies were conducted at the end of the study. No mortality 
occurred during the course of the study. Additionally, no adverse clinical signs were observed during 
the study and no adverse findings were noted at necropsy. The relatively high dose tested in this study 
did not give rise to any toxicity and therefore the acute LD50 for Cry35Ab1 protein could not be 
determined and is estimated to be higher than 1850 mg Cry35Ab1 per kg body weight.  
 
Finally, a mixture of Cry34Ab1 and Cry35Ab1 proteins was evaluated for acute oral toxicity in mice 
and the highest dose tested was 5000 mg of test material per kg body weight. When adjusted for purity 
of the test material (54% pure for Cry34Ab1 protein and 37% pure for the Cry35Ab1 protein (Brooks 
and DeWildt, 2000c), the mixture contained 482 mg Cry34Ab1 protein per kg body weight and 1520 
mg Cry35Ab1 protein per kg body weight. During the two-week observation period, mortality and/or 
clinical or behavioural signs of pathology as well as body weights were recorded. Gross necropsies 
were conducted at the end of the study. No mortality occurred during the course of the study. 
Additionally, no adverse clinical signs were observed during the study that was treatment related and 
no adverse findings were noted at necropsy. Therefore, the acute oral LD50 for a mixture of Cry34Ab1 
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and Cry35Ab1 proteins could not be determined and is estimated to be higher than 2000 mg/kg body 
weight of an equimolar mixture of the pure Cry34Ab1 and Cry35Ab1 proteins. 
                                                                                                                                                                                                    
Acute oral exposure of CP4 EPSPS protein in rodents 
Monsanto has conducted an acute toxicity study (MSL-13077, 1993) conducted in mice. Male and 
female CD-1 mice were dosed by gavage with the CP4-EPSPS protein produced in E. Coli, purity of 
the protein is >90 % (Harrison et al. 1996). 
 
The study was conducted in general compliance with the EPA FIFRA GLP (40 CFR Part 160), EU-
directive 88/320/EC) and acute oral toxicity guidelines of U.S. EPA and OECD (U.S. EPA Health 
Effects Test Guidelines. OPPTS 870.1100; Acute Oral Toxicity (August 1998), OECD Guideline for 
Testing of Chemicals; Method No. 420: Acute Oral Toxicity-Fixed Dose Method; July 17, 1992). A 
total of 100 animals (50 males and 50 females) were used in the study, ranging from 5.5 weeks to 7 
weeks of age. Test groups were randomized for weight and comprised 10 CD-1 mice of each sex per 
group. 
 
The protein preparation containing the CP4 EPSPS was administered as a single dose by gavage to 
three groups of the mice at dosages of 49, 154 and 572 mg/kg body weight respectively. These doses 
correspond to 40, 100 and 400 mg/kg of CP4 EPSPS protein based on the level of purity of the protein 
and ELISA analyses of the dosing solutions. A control group received bovine serum albumin (BSA) at 
a dosage of 363 mg/kg in the same solution and delivery volume as the test substance. The second 
control group was administered the carrier solution only, 50 mM sodium bicarbonate. 
 
At defined stages throughout the duration of the study, clinical observations were performed for 
mortality and signs of toxicity, and body weights and food consumption measured. Signs of toxicity 
include such occurrences as changes in the skin and fur, eyes and mucous membranes, respiratory, 
autonomic and central nervous systems as well as behavioral changes. At the termination of the study 
(day 8-9), animals were sacrificed, examined for gross pathology and numerous tissues were collected. 
 
Tissues retained from the animals included aorta, adrenals, brain, colon, oesophagus, eyes, gall 
bladder, heart, kidneys, lung, liver, lymph nodes, muscle, ovaries, pancreas, pituitary, prostate, rectum, 
salivary gland, seminal vesicles, skin, spinal cord, spleen, stomach, testes, thymus, uterus and bladder. 
Hollow organs were opened and examined. 
 
The results of the study showed no statistically significant differences in group mean body weights, 
cumulative weight gains or food consumption in any of the groups treated with either BSA or the CP4 
protein, when compared with the carrier control group. The data were evaluated according to a 
decision-tree analysis procedure which, depending on the results of early statistical tests, determined 
further statistical analysis applied to detect group differences and analyse for trends. All animals 
survived to the scheduled termination of the study, and there were no clinical signs observed that 
could be related to the test material.  
 
EHL decision-tree analysis (two-tailed): Terminal body weights were evaluated by decision-tree 
statistical analyses which, depending on the results of tests for normality (2) and homogeneity of 
variances [Bartlett’s,Test (3)], utilized either parametric [Dunnett’s Test (1) and Linear Regression 
(4)] or nonparametric [Kruskal-Wallis (5), Jonckheere’s (6) antior Mann-Whitney (7) Tests] routines 
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4.3.1.2 Repeated dose toxicity testing 
 
Repeated dose 14-day oral toxicity study of PAT protein in rodents 
Bayer Crop Sciences has performed a sub-chronic oral toxicity study of the PAT-protein in rats 
(Pfister et al. 1996).  The study was performed in accordance with the principles of Good Laboratory 
of O.E.C.D. (Organization for Economic Cooperation and Development) and Principles of Good 
Laboratory Practice, 1992. Good Laboratory Practice (GLP) in Switzerland, Procedures and 
Principles, March 1986 and the Japanese Ministry of Agriculture, Forestry and Fisheries: On Good 
Laboratory Practice Standards for Toxicological Studies on Agricultural Chemicals, Agricultural 
Production Bureau, 59 NohSan Notification Number 3850, August 10, 1984. Test guidelines: The 
study procedures mostly conform to OECD Guidelines for Testing of Chemicals, number 407 
"Repeated Dose 28-day Oral Toxicity Study in Rodents", adopted by the Council on July 27, 1995. 
According to the OECD guidelines the duration of exposure should normally be 28 days although a 
14-day study may be appropriate in certain circumstances; justification for use of a 14-day exposure 
period should be provided. The duration of this repeated dose oral toxicity was 14-day exposure 
period. No justification for using 14-days has been given in the dossier of the applicant. 
 
Animals of group 1 received a standard diet and rats of groups 2, 3 and 4 were fed a low protein diet, 
which was adjusted to similar protein content as that of group 1 by using soybean derived protein. 
Protein was administered by feed admixture in powdered diet to Wistar rats of 0 (group 1), 0.5 % 
PAT-protein + 4.5 % soyprotein (group 2), 5 % PAT-protein (group 3) and 5% soyprotein (group 4) 
for a period of 14 days. The study comprised four groups each with five male and five female rats. The 
mean intake of PAT-protein over the treatment period was: 0.712 mg/kg body weight/day for males in 
group 2; 703 mg/kg body weight/day for females in group 2; 7965 mg/kg body weight/day for males 
in group 3 and 7619 mg/kg body weight/day for females in group 3. 
 
The results showed no unscheduled deaths or clinical signs. Food consumption and body weights were 
unaffected by treatment. No treatment-related changes were seen in hematology or urinalysis 
parameters. Organ weight data, macroscopical and microscopical findings did not distinguish treated 
groups from controls. 
 
The only changes which might be attributed to treatment were observed in clinical biochemistry 
parameters. They consisted of a slightly lower glucose level in males of group 4, slightly higher total 
cholesterol and phospholipid levels in male rats of groups 2, 3 and 4 and slightly higher triglyceride 
level in females of group 4 when compared with rats of group 1. Animals of group 4 received no PAT-
protein but - with respect to the protein content - a diet slightly similar to that of groups 2 and 3. The 
above changes are according to the applicant considered to reflect differences in the dietary 
composition and to be unrelated to PAT Protein itself. Further, the increased total cholesterol and 
phospholipid levels are found to be in a similar range when comparing group 3 (low protein diet + 5 % 
PAT-protein) with group 4 (low protein diet + 5 % soya protein). The results may suggest a similar 
nutritional value of both proteins.  
 
Repeated dose 28-day oral toxicity study of Cry34Ab1 and Cry35Ab1 protein in rodents 
Five male and five female CD-1 mice per group were given test diets formulated to supply 0/0, 
1.97/0.078, 19.7/0.78, or 197/7.8 milligrams Cry34/35Ab1 proteins respectively, per kilogram body 
weight per day (mg/kg/day, mkd). These values corresponded to nominal time-weighted average 
concentrations of 0/0, 1.84/0.073, 18.4/0.73, and 195/7.7 mg/kg/day for males and 0/0, 2.13/0.085, 
19.8/0.79, and 202/8 mg/kg/day for females, of Cry34/35Ab1 proteins, respectively. Actual 
concentrations of Cry34/35Ab1 proteins were higher in all dose groups based on analytical results, 
with the exception of the lower concentration of Cry35Ab1 in the low-dose group. Additional groups 
of five male and five female mice were fed diets containing bovine serum albumin (BSA) at the rate of 
204.8 mg/kg body weight /day to serve as a protein control group. The nominal time-weighted average 
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concentrations of BSA were 189.3 and 202.1 mg/kg/day for males and females, respectively. The 
Cry34/35Ab1 protein treatment groups were statistically compared to BSA-control group. Parameters 
evaluated were daily cage-side observations, weekly detailed clinical observations, ophthalmic 
examinations, body weights, feed consumption, hematology, clinical chemistry, selected organ 
weights, and gross and histopathologic examinations. There were no treatment-related effects on any 
parameter (Juberg et al 2009). 
 
The study evaluated the potential toxicity of the combination of microbially derived Cry34Ab1 and 
Cry35Ab1 insecticidal crystal proteins, referred to as Cry34/35Ab1, in mice following dietary 
administration for 28 days. Five male and five female CD-1 mice per group were given test diets 
formulated to supply 0/0, 1.97/0.078, 19.7/0.78, or 197/7.8 milligrams Cry34/35Ab1 proteins 
respectively, per kilogram body weight per day (mg/kg/day, mkd). These values corresponded to 
nominal time-weighted average concentrations of 0/0, 1.84/0.073, 18.4/0.73, and 195/7.7 mg/kg/day 
for males and 0/0, 2.13/0.085, 19.8/0.79, and 202/8 mg/kg/day for females, of Cry34/35Ab1 proteins, 
respectively. Actual concentrations of Cry34/35Ab1 proteins were higher in all dose groups based on 
analytical results, with the exception of the lower concentration of Cry35Ab1 in the low-dose group. 
Additional groups of five male and five female mice were fed diets containing of 204.8 mg/kg body 
weight /day bovine serum albumin (BSA) serving as a protein control group. The nominal time-
weighted average concentrations of BSA were 189.3 and 202.1 mg/kg/day for males and females, 
respectively. The Cry34/35Ab1 protein treatment groups were statistically compared to BSA-control 
group. Parameters evaluated were daily cage-side observations, weekly detailed clinical observations, 
ophthalmic examinations, body weights, feed consumption, hematology, clinical chemistry, selected 
organ weights, and gross and histopathological examinations. There were no treatment-related effects 
on any parameter (Thomas et al. 2006, Dow AgroSciences unpublished internal report.).  
 
 
4.3.2 Toxicological assessment of the whole GM food/feed 
 
The applicant has provided a nutritional study on broilers using the triple stacked event 
59122x1507xNK603 maize as test material.  
 
A poultry feeding study was conducted with diets containing grain from 59122x1507xNK603 maize. 
According to the applicant, the poultry feeding study with the 59122x1507xNK603 maize is relevant 
for the safety assessment of the 59122xNK603 maize. The 59122x1507xNK603 maize has been 
obtained from traditional breeding methods between progeny of three genetically modified maizes. 
Since the 59122x1507xNK603 maize contains the 59122 maize insert and the NK603 maize insert, the 
applicant concludes that absence of adverse effects of the 59122x1507xNK603 maize grain in a 42-
day poultry study provides the necessary scientific information to also infer the absence of adverse 
effects on broiler chickens from feeding with 59122xNK603 maize. 
 
The poultry feeding study with diets containing grain from 59122x1507xNK603 maize was conducted 
over a 42-day period. The 59122x1507xNK603 maize grains used in this study were produced from 
plants that received either two sequential treatments with glufosinate herbicide, two sequential 
treatments with glyphosate herbicide or treatments of glyphosate followed by glufosinate herbicide. 
For comparison, diets containing grain from non-GM maize with comparable genetic background and 
from three types of commercial maize (33P66, 33J56 and 33R77) were also fed to the chickens. The 
chickens fed the 59122 x1507xNK603 maize grain, non-GM control maize grain or commercial maize 
grain were observed for overall health, behavioral changes and/or evidence of toxicity. Body weights 
and feed weights were measured every 7 days. The body weight parameters evaluated at the end of the 
42-day study included carcass yield, thighs, breasts, wings, legs, abdominal fat, kidneys and whole 
liver. Mortality, weight gain, feed efficiency, organ yields, carcass and parts (breast, thigh, wing and 
leg) yields and abdominal fat were analyzed for statistical differences between the chickens fed the 




EFSA/GMO/UK/2005/20 – Genetically modified maize 59122 x NK603 
 
59122x1507xNK603 maize diet and chickens fed the non-GM control maize diet at p≤0.05. In 
addition, tolerance intervals were calculated for performance and carcass traits that are expected to 
contain, with 95% confidence, 99% of the values obtained for the chickens fed the three commercial 
non-GM maize diets. Data from the chickens fed the 59122x1507xNK603 maize diet and chickens fed 
the diet with non-GM control maize with comparable genetic background were then evaluated to 
determine if observed values were contained within each tolerance interval. 
 
No statistically significant differences were observed on mortality, body weight, body weight gain or 
feed efficiency between chickens fed a diet containing grain from 59122x1507xNK603 maize or 
chickens fed a non-GM control maize diet. No statistically significant differences were observed for 
overall organ yields between chickens fed a diet containing grain from 59122x1507xNK603 maize or 
chickens fed a non-GM control maize diet. Kidney yields, within females, were slightly lower for the 
59122x1507xNK603 maize fed chickens compared to chickens fed the non-GM control maize diet. 
However, the observed values for female kidney yield for both the 59122 x 1507 x NK603 maize fed 
and the non-GM control fed chickens are still well within the tolerance range calculated from the 
kidney yields from chickens fed the three commercial non-GM maize diets. 
 
No statistically significant differences were observed for carcass yield, breast, thigh, wing and leg 
yield or overall abdominal fat between chickens fed a diet containing grain from 59122x1507xNK603 
maize or chickens fed a non-GM control maize diet. Abdominal fat, within males, was slightly lower 
for the 59122 x 1507 x NK603 maize fed chickens compared to chickens fed the non-GM control 
maize diet. However, the observed values for male abdominal fat for both the 59122 x 1507 x NK603 
maize fed and the non-GM control fed chickens are still well within the tolerance range calculated 
from the abdominal fat from chickens fed the three commercial non-GM maize diets. 
 
Based on the results from this study, the applicant concludes that 59122xNK603 maize is nutritionally 
equivalent to non-GM maize with comparable genetic background and to commercial maize. In 
addition, the results obtained further indicate the safety of the Cry34Ab1, Cry35Ab1, PAT and CP4 
EPSPS proteins expressed in 59122xNK603 maize.  
 
Further, no subchronic adverse effects were observed in a 90-day study where rats were fed with diets 
prepared with the 59122 maize (Malley et al 2007). A published 90-day study in rats conducted with 
diets prepared with NK603 resulted in no consistent differences in the measured clinical, biochemical 
and histological parameters, except for slightly elevated levels of average corpuscular volume and 
average corpuscular haemoglobin in female rats administered the high dose (Hammond et al. 2004).  
 
According to a two year feeding study performed by Séralini and co-workers (Séralini et al. 2012), the 
inclusion of NK603 in the animal feed and/or the use of Roundup herbicide either on maize crops or 
added in drinking water, led to several severe pathologies among the animals, including an increased 
mortality rate, higher rate of tumour development, kidney nephropathies and hormone disruptions etc. 
The study by Séralinis group has, however, been thoroughly investigated by regulatory authorities in 
several countries (e.g. Belgium, Denmark, France, Germany, Italy and the Netherlands) as well as 
EFSA and The Norwegian Scientific Committees Panel on GMOs (VKM 2012), and deemed to be of 




4.4 Allergenicity assessment 
 
The strategies used when assessing the potential allergenic risk focuses on the characterisation of the 
source of the recombinant protein, the potential of the newly expressed protein to induce sensitisation, 
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or to elicit allergic reactions in already sensitised individuals and whether the transformation may have 
altered the allergenic properties of the modified food. A weight-of-evidence approach is 
recommended, taking into account all of the information obtained with various test methods, since no 
single experimental method yields decisive evidence for allergenicity (EFSA 2006, EFSA 2011a).  
 
Most food allergies are mediated by IgE and are characteristic of type-I reactions. According to 
Regulation (EC) No. 1829/2003 the applicant shall assess post-translational modifications of 
expressed proteins, and assess gluten-sensitive enteropathy or other enteropathies which are not IgE-
mediated. 
 
Most of the major food and respiratory IgE-allergens have been identified and cloned, and their 
protein sequences incorporated into various databases. As a result, novel proteins can be routinely 
screened for amino acid sequence homology with, and structural similarity to, known human IgE-
allergens using an array of bioinformatic tools. Sequence homology searches comparing the structure 
of novel proteins to known IgE-allergens in a database are conducted using various algorithms such as 
FASTA to predict overall structural similarities. According to FAO/WHO (2001) in cases where a 
novel protein and a known IgE-allergen have more than 35% identity over a segment of 80 or greater 
amino acids, IgE cross-reactivity between the novel protein and the allergen should be considered a 
possibility.  
 
4.4.1 Assessment of allergenicity of the newly expressed protein 
 
The applicant has performed a weight-of-evidence approach (Metcalfe et al.,1996; FAO/WHO 2001; 
Codex 2003) for an overall assessment of the IgE allergenic potential of the Cry34Ab1, Cry35Ab1, 
PAT and CP4 EPSPS proteins, which includes: 
  
• assessing the allergenicity potential of the source of the gene 
• homology searches with known protein allergens 
• susceptibility to in vitro simulated digestion and thermolability 
• evaluation of protein glycosylation 
• assessment of protein exposure 
 
 
These assessments have previously been described by the applicant for the single maize events NK603 
(EFSA-GMO-RX-NK603) and 59122 (EFSA-GMO-NL-2005-12, EFSA-GMO-NL-2005-23), and 
were based on the following aspects:  
 
i) The sources of the transgenes genes:  B. thuringiensis (cry-genes), S. 
viridochromogenes (pat), and Agrobacterium sp. strain CP4 (cp4 epsps) have no 
history of causing allergy 
ii) History of safe use of Cry proteins as microbial pesticides, no indications of Cry 
proteins originating from Bacillus thuringiensis having harmful effects on the 
health of humans and animals 
iii) The  Cry34Ab1 and Cry35Ab1 proteins do not show significant amino acid 
sequence similarity to known protein toxins, and don’t share immunologically 
relevant sequence similarity with known allergens  
iv) The Cry34Ab1 and Cry35Ab1 proteins are rapidly degraded, as shown by SDS-
PAGE, under simulated gastric fluid digestive conditions  
v) The Cry34Ab1 and Cry35Ab1 proteins have been considered as heat labile, since 
biological activity of Cry1F was lost after exposure at 75oC for 30 minutes, while 
the Cry34Ab1 and Cry35Ab1 proteins lost theirs after exposure at 60 oC for 30 
minutes  
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vi) The proteins Cry34Ab1, Cry35Ab1 are not glycosylated  
vii) The PAT protein has been the subject of previous safety assessments for 
genetically modified plants and found to have no potential for allergenicity  
viii) The PAT protein lacks homology to known toxins or allergenic proteins  
ix) Rapid degradation of the PAT protein in simulated gastric fluids 
x) CP4 EPSPS does not resemble any characteristics of known IgE-allergens, and no 
significant homologies between the amino acid sequences of the CP4 EPSPS 
protein and IgE-allergenic proteins have been found  
xi) The CP4 EPSPS protein is readily degraded in simulated digestive fluids and is not 
glycosylated  
xii) CP4 EPSPS is considered as heat labile  
 
 
The information listed above indicates that the newly expressed proteins in maize 59122 x NK603 
lack IgE allergenic potential with regard to human and animal health. However, it does not cover 
allergic reactions that are not IgE mediated, e.g. some gluten-sensitive enteropathies or other 
enteropathies that are not IgE-mediated. 
 
 
4.4.2 Assessment of the allergenicity of the whole GM plant 
 
Allergenicity of the maize 59122 x Nk603 could be increased as an unintended effect of the random 
insertion of the transgene in the genome of the recipient, e.g. through qualitative or quantitative 
modifications of the expression of endogenous proteins. However, given that no biologically relevant 
agronomic or compositional changes have been identified in maize 59122 x NK603 or the parental 
events 59122 and NK603 with the exception of the introduced traits, no increased allergenicity is 




According to the EFSA guidance document for risk assessment of food and feed from GM plants 
(EFSA 2011b), adjuvants are substances that, when co-administered with an antigen increase the 
immune response to the antigen and therefore might increase the allergic response. In cases when 
known functional aspects of the newly expressed protein or structural similarity to known strong 
adjuvants may indicate possible adjuvant activity, the possible role of these proteins as adjuvants 
should be considered. As for allergens, interactions with other constituents of the food matrix and/or 
processing may alter the structure and bioavailability of an adjuvant and thus modify its biological 
activity. 
 
Only two of the 10 Cry proteins that are currently used in genetically modified plants, Cry1Ab and 
Cry1Ac, have been studied experimentally regarding adjuvant effects. To the knowledge of the VKM 
GMO Panel, adjuvant effects have not been investigated for the other 8 Cry proteins used in GM 
plants, or for other groups of Cry proteins. Immunological mapping of the systemic and mucosal 
immune responses to Cry1Ac have shown that mice produce both systemic IgM and IgG and secretory 
IgA following intraperitonal and intragastric immunisation. In a mouse study by Vazquez et al., the 
adjuvant effect of Cry1Ac was found to be as strong as the effect of cholera toxin (CT) (Vazquez et al. 
1999). The adjuvant effect of CT is thus a relevant basis for comparison in a risk assessment of 
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“Bystander sensitisation” 
"Bystander sensitisation” can occur when an adjuvant in food, or an immune response against a food 
antigen, results in an increased permeability of the intestinal epithelium for other components in food. 
Previously it was assumed that the epithelial cells of the intestine were permanently "glued together" 
by the so-called "tight junctions". More recent knowledge shows that these complex protein structures 
are dynamic and can be opened up by different stimuli. 
 
Both in vitro and in vivo experiments have demonstrated that when an IgG response which can result 
in a complement activation (among other) is not balanced by an IgA response, the epithelial barrier 
can be opened and unwanted proteins are able to enter the body (bystander-penetration) and lead to 
allergic sensitisation (Brandtzaeg P, Tolo K 1977;  Lim PL, Rowley D1982). 
 
Additional information can be found in the report by VKM on Cry-proteins and adjuvanticity: “Health 
risk assessment of the adjuvant effects of Cry proteins from genetically modified plants used in food 
and fodder” (VKM 2012b) 
 
 
4.5 Nutritional assessment of GM food/feed 
 
Compositional analyses of maize 59122 x NK603 indicate nutritional equivalence to the non-GM 
control maize with comparable genetic background and to the published range of values in the 
literature. The applicant has provided a nutritional study on broilers using the triple stacked event 
59122x1507xNK603 maize as test material.  
 
 
4.5.1  Intake information/exposure assessment 
 
Net import of maize staple, e.g. flour, starch and mixed products, in Norway in 2007 was 7600 tons, 
corresponding to 4.4 g dry weight/person/day or an estimated daily energy intake for adults to be 0.6 
% (Vikse 2009). The production of maize porridge for children in 2007 was about 37.5 tons, 
corresponding to a daily intake of 1.7 g/day or an estimated daily energy intake to be 0.6 % for a 6 
month child (Vikse 2009). 
The expression levels of the Cry34Ab1, Cry35Ab1 and CP4 EPSPS proteins in grain from 59122 x 
NK603 maize ranged from 21.8 to 53.6 µg/g grain dry weight, from 0.53 to 3.31 µg/g grain dry 
weight, and from 3.06 to 16.4 µg/g grain dry weight, respectively. Expression of the PAT protein in 
59122 x NK603 grain ranged from below the lower limit of quantitation of the assay to 0.44 µg/g 
grain dry weight.  
 
Since all foods from maize are derived from grains, the estimated maximum daily intake for a 
Norwegian adult of Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins is calculated to be 236 µg, 
15 µg, 2 µg and 28 µg, respectively, based on grain dry weight. These levels are several orders of 
magnitude below the levels shown to have no effect in laboratory toxicology testing. Also, these levels 
are considerably below the proposed threshold of toxicological concern (TTC) level of 1800 
µg/person/day (Class 1, oral exposure) for chemicals considered to have a low potential for toxicity 
based on metabolism and mechanistic data (Vermeire et al., 2010). Some farm animals such as pigs 
and poultry which are fed diets formulated with up to 80% maize, are exposed to Cry1F, 
Cry34Ab1 and Cry35Ab1 levels that are close to 100 times above the TTC level of 1,8 
mg/animal/day. 
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This dietary exposure assessment is very conservative. It assumes that all maize consumed consists of 
59122 x NK603 maize and that protein levels are not reduced by processing. The comparable 
composition and nutritional value of the 59122 x NK603 maize, together with the results of the 
assessment of dietary intake and nutritional impact, indicate that food products derived from 
59122 x NK603 maize are nutritionally equivalent to food products derived from commercial 
maize. Hence, anticipated dietary intake, of maize derived foods and feeds is not expected to 
change.  
 
4.5.2  Nutritional assessment of feed derived from the GM plant 
 
Based on the compositional analyses comprising proximates, minerals, fatty acids, amino acids, 
vitamins, secondary metabolites and anti-nutrients of forage and grain samples from 59122 x NK603 
maize; nutritional equivalence shown in a poultry feeding study; and, safety evaluation of the 
Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins expressed in 59122 x NK603 maize, the 
59122xNK603 maize and derived feed products seem to be substantially equivalent to, nutritionally 
equivalent, and as safe as commercial maize and derived feed products.  
 
 
4.5.3 Post-Market Monitoring of GM food/feed 
 
Based on the safety assessment discussed throughout section 4.3, no risks to human and animal health 
have been identified from the human food and animal feed use of 59122xNK603 maize as compared 
to human food and animal feed use of commercial maize. In addition, the nutritional characteristics 
and use of food, feed and processed products derived from 59122xNK603 maize seem to be similar to 




Whole food feeding study has not been performed using 59122 x NK603 maize.  The applicant has, 
however, provided a nutritional study on broilers using the triple stacked event 59122 x 1507 x NK603 
maize as test material. Bioinformatics analyses have not revealed expression of any known ORFs in 
the parental maize lines, and none of the newly expressed proteins show resemblance to any known 
toxins or IgE allergens. Nor have the newly expressed proteins been reported to cause IgE mediated 
allergic reactions. Some studies have however indicated a potential role of Cry-proteins as adjuvants 
in allergic reactions. 
 
Acute and repeated toxicity tests in rodents have not indicated toxic effects of the newly expressed 
proteins. However, these tests do not provide any additional information about possible adverse effects 
of the stacked event maize 59122 x NK603. 
 
Based on the current knowledge, the VKM GMO Panel concludes that 59122 x NK603 maize is 
nutritionally equivalent to its conventional maize, and that it is unlikely that newly expressed proteins 
will introduce a toxic or allergenic potential of food/feed derived from maize 59122 x NK603 
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5 Environmental risk assessment 
 
5.1 Unintended effects on plant fitness due to the genetic modification 
 
Maize (Zea mays L.) is an annual plant and member of the grass family Poacea. The species, 
originating from Central America, is highly domesticated and generally unable to survive in the 
environment without management intervention (Eastham & Sweet 2002).  Maize propagates entirely 
by seed produced predominantly by cross-pollination (OECD 2003). In contrast to weedy plants, 
maize has a pistillate inflorescence (ear) with a cob enclosed with husks. Due to the structure of the 
cob, the seeds remain on the cob after ripening and natural dissemination of the kernels rarely occurs.  
 
The survival of maize in Europe is limited by a combination of absence of a dormancy phase resulting 
in a short persistence, high temperature requirements for germination, low frost tolerance, low 
competitiveness and susceptibility to plant pathogens, herbivores and climatic conditions (van de Wiel 
et al. 2011). Maize plants cannot survive temperatures below 0ºC for more than 6 to 8 hours after the 
growing point is above ground  (OECD 2003), and in Norway and most of Europe, maize kernels and 
seedlings do not survive the winter cold (Gruber et al. 2008). Observations made on cobs, cob 
fragments or isolated grains shed in the field during harvesting indicate that grains may survive and 
overwinter in some regions in Europe, resulting in volunteers in subsequent crops. The occurrence of 
maize volunteers has been reported in Spain and other European regions (e.g. Gruber et al. 2008). 
However, maize volunteers have been shown to grow weakly and flower synchronously with the 
maize crop (Palaudelmás et al. 2009). Cross-pollination values recorded were extremely variable 
among volunteers, most probably due to the loss of hybrid vigour and uniformity. Overall cross-
pollination to adjacent plants was estimated as being low.  
 
Despite cultivation in many countries for centuries, seed-mediated establishment and survival of maize 
outside cultivation or on disturbed land in Europe is rare (BEETLE Report 2009). Maize plants 
occasionally grow in uncultivated fields and by roadsides. However the species is incapable of 
sustained reproduction outside agricultural areas in Europe and is non-invasive of natural habitats 
(Eastham & Sweet 2002; Devos et al. 2009). There are no native or introduced sexually cross-
compatible species in the European flora with which maize can hybridise and form backcross progeny 
(Eastham & Sweet 2002; OECD 2003). The only recipient plants that can be cross-fertilised by maize 
are other cultivated maize cultivars.  
 
It is considered very unlikely that the establishment, spread and survival of maize 59122 x NK603 
would be increased due to the insect resistance and herbicide tolerance traits. The herbicide tolerant 
trait can only be regarded as providing a selective advantage for the GM maize plant where and when 
glufosinate ammonium-based herbicides are applied. Glufosinate ammonium-containing herbicides 
have been withdrawn from the Norwegian market since 2008, and the substance will be phased out in 
the EU in 2017 for reasons of reproductive toxicity. Similarly insect resistance against certain 
lepidopteran and coleopteran pests provides a potential advantage in cultivation of 59122 x NK603 
under infestation conditions. It is considered very unlikely that maize 59122 x NK603 plants or their 
progeny will differ from conventional maize cultivars in their ability to survive as volunteers until 
subsequent seasons, or to establish feral populations under European environmental conditions.  
 
Field trials carried out by the applicant do not indicate altered fitness of maize 59122 x NK603 relative 
to its conventional counterpart. A series of field trials with maize 59122 x NK603 were carried out 
across 6 locations in the USA and Canada in 2003 (application EFSA/GMO/UK/2005/20). In addition, 
agronomic observations performed in field trials in the EU in 2004 (Spain, Hungary and Bulgaria) 
have been provided by the applicant in application EFSA/GMO/UK/2005/30 (maize stack 59122 x 
1507 x NK603). Information on phenotypic (e.g. crop physiology, morphology, development) and 
agronomic (e.g. grain yield) characteristics was provided to assess the agronomic performance of 
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maize 59122 x NK603 in comparison with its conventional counterpart (see section 3.1). Data from 
the field trials in the USA and Canada shows some statistical significant differences for plant height, 
time to silking and pollen shed). These differences were however small in magnitude and were not 
consistently observed over locations. In the European field trials mean time to silking and plant height 
values across locations for the maize 59122 x NK603 and control maize were statistically different 
(p<0.05). The VKM GMO Panel is of the opinion that they do not raise any environmental safety 
concern. 
 
In addition to the data presented by the applicant, the VKM GMO Panel is not aware of any scientific 
reports indicative of increased establishment or spread of maize 59122 x NK603, or changes to its 
survivability (including over-wintering), persistence or invasive capacity. Because the general 
characteristics of maize 59122 x NK603 are unchanged, insect resistance, glufosinate and glyphosate 
tolerance are not likely to provide a selective advantage outside of cultivation in Europe. The VKM 
GMO Panel is of the opinion that the likelihood of unintended environmental effects based on 
establishment and survival of maize 59122 x NK603 will not differ from that of conventional maize 
varieties. 
 
5.2  Potential for gene transfer 
 
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic material, 
either through horizontal gene transfer of DNA, or vertical gene flow via pollen or seed dispersal. 
Exposure of microorganisms to transgenic DNA occurs during decomposition of plant material 
remaining in the field after harvest or comes from pollen deposited on cultivated areas or the field 
margins. Transgenic DNA is also a component of a variety of food and feed products derived from 
maize 59122 x NK603. This means that micro-organisms in the digestive tract in humans and animals 
(both domesticated animals and other animals feeding on fresh or decaying plant material from the 
transgenic maize line) may be exposed to transgenic DNA. 
 
Maize is the only representative of the genus Zea in Europe, and there are no cross-compatible wild or 
weedy relatives outside cultivation with which maize can hybridise and form backcross progeny 
(Eastham & Sweet 2002; OECD 2003). Vertical gene transfer in maize therefore depends on cross-
pollination with other conventional or organic maize varieties. All maize varieties which are cultivated 
in Europe can interbreed. In addition, unintended admixture/adventitious presences of genetically 
modified material/transgenes in seeds represent a possible way for gene flow between different 
production systems.  
 
 
5.2.1 Plant to micro-organisms gene transfer 
 
Experimental studies have shown that gene transfer from transgenic plants to bacteria rarely occurs 
under natural conditions and that such transfer depends on the presence of DNA sequence similarity 
between the DNA of the transgenic plant and the DNA of the bacterial recipient (Nielsen et al. 2000; 
De Vries & Wackernagel 2002, reviewed in EFSA 2004, 2009a; Bensasson et al. 2004; VKM 2005c). 
 
Based on established scientific knowledge of the barriers for gene transfer between unrelated species 
and the experimental research on horizontal transfer of genetic material from plants to 
microorganisms, there is today little evidence pointing to a likelihood of random transfer of the 
transgenes present in maize 59122 x NK603 to unrelated species such as bacteria.   
 
It is however pointed out that there are limitations in the methodology used in these experimental 
studies (Nielsen & Townsend 2004). Experimental studies of limited scale should be interpreted with 
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caution given the scale differences between what can be experimental investigation and commercial 
plant cultivation.  
 
Experiments have been performed to study the stability and uptake of DNA from the intestinal tract in 
mice after M13 DNA was administered orally. The DNA introduced was detected in stool samples up 
to seven hours after feeding. Small amounts (<0.1%) could be traced in the blood vessels for a period 
of maximum 24 hours, and M13 DNA was found in the liver and spleen for up to 24 hours (Schubbert 
et al. 1994). By oral intake of genetically modified soybean it has been shown that DNA is more stable 
in the intestine of persons with colostomy compared to a control group (Netherwood et al. 2004). No 
GM DNA was detected in the faeces from the control group. Rizzi et al. (2012) provides an extensive 
review of the fate of feed-derived DNA in the gastrointestinal system of mammals.  
 
In conclusion, the VKM GMO Panel consider it is unlikely that the introduced gene from maize 59122 
x NK603 will transfer and establish in the genome of microorganisms in the environment or in the 
intestinal tract of humans or animals. In the rare, but theoretically possible case of transfer of the cry, 
pat and CP4 EPSPS genes from 59122 x NK603 to soil bacteria, no novel property would be 
introduced into or expressed in the soil microbial communities; as these genes are already present in 
other bacteria in soil. Therefore, no positive selective advantage that would not have been conferred 
by natural gene transfer between bacteria is expected. 
 
 
5.2.2 Plant to plant gene flow 
 
Considering the intended uses of maize 59122 x NK603 (excluding cultivation) and the physical 
characteristics of maize seeds, possible pathways of gene dispersal are grain spillage and dispersal of 
pollen from potential transgenic maize plants originating from accidental grain spillage during 
transport and/or processing.  
 
The extent of cross-pollination to other maize cultivars will mainly depend on the scale of accidental 
release during transportation and processing, and on successful establishment and subsequent 
flowering of the maize plant. For maize, any vertical gene transfer is limited to other varieties of Zea 
mays plants as populations of sexually compatible wild relatives of maize are not known in Europe 
(OECD 2003). 
 
Survival of maize plants outside cultivation in Europe is mainly limited by a combination of low 
competitiveness, absence of a dormancy phase and susceptibility to plant pathogens, herbivores and 
frost. As for any other maize cultivars, GM maize plants would only survive in subsequent seasons in 
warmer regions of Europe and are not likely to establish feral populations under European 
environmental conditions. In Norway, maize plants from seed spillage occasionally grow on tips, 
waste ground and along roadsides (Lid & Lid 2005). 
 
The flowering of occasional feral GM maize plants origination from accidental release during 
transportation and processing is however unlikely to disperse significant amounts of GM maize pollen 
to other maize plants. Field observations performed on maize volunteers after GM maize cultivation in 
Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that cross-
pollinated neighbour plants only at low levels (Palaudelmás et al. 2009).  
 
As maize 59122 x NK603 has no altered survival, multiplication or dissemination characteristics, the 
VKM GMO Panel is of the opinion that the likelihood of unintended environmental effects as a 
consequence of spread of genes from this GM maize in Norway will not differ from that of 
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conventional maize varieties. The likelihood of cross-pollination between cultivated maize and the 




5.3 Interactions between the GM plant and target organisms 
 
Maize 59122 was transformed to co-express the cry34Ab1 and cry35Ab1 genes from Bacillus 
thuringiensis. The binary insecticidal toxin is made of two components, the Cry34Ab1 and Cry35Ab 
proteins, acting together and conferring resistance to coleopteran insect pests belonging to the genus 
Diabrotica, such as larvae of western corn rootworm (WCR; D. virgifera virgifera) and the northern 
corn rootworm (NCR; D. barberi). WCR has been introduced to Europe from North America, where it 
is native and widespread (Miller et al. 2005, ref. EFSA 2013). D. virgifera virgifera was first detected 
in Serbia in 1992, but has since spread across the continent, resulting in well-established populations 
in approximately 19 European countries (EC 2012). There have been no reports of D. virgifera 
virgifera in Norway (http://www.faunaeur.org/distribution.php) 
 
Considering the intended uses of maize 59122 x NK603, excluding cultivation, the environmental 
exposure is limited to exposure through manure and faeces from the gastrointestinal tract mainly of 
animals fed on the GM maize as well as to the accidental release into the environment of GM seeds 
during transportation and processing and subsequently to potential occurrence of sporadic feral plants. 
Thus the level of exposure of target organisms to Cry34Ab and Cry35Ab1 proteins is likely to be 
extremely low and of no ecological relevance. 
 
 
5.4 Interactions between the GM plant and non-target organisms (NTOs) 
 
Considering the intended uses of maize stack 59122 x NK603, excluding cultivation, the 
environmental risk assessment is concerned with accidental release of GM maize viable grains into the 
environment during transportation and processing, and exposure through manure and faeces from the 
gastrointestinal tracts of animals fed the GM maize.  
 
Cry proteins are degraded by enzymatic activity in the gastrointestinal tract, meaning that only very 
low amounts would remain intact to pass out in faeces (e.g. Lutz et al. 2005, Guertler et al. 2008; Paul 
et al. 2010).  There would subsequently, be further degradation of the Cry proteins in the manure and 
faeces due to microbial processes. In addition, there will be further degradation of Cry proteins in soil, 
reducing the possibility for the exposure of potentially sensitive non-target organisms. Although Cry 
proteins bind rapidly on clays and humic substances in the soil and thereby reducing their availability 
to microorganisms for degradation, there is little evidence for the accumulation of Cry proteins from 
GM plants in soil (Icoz & Stotzky 2009). 
 
Data supplied by the applicant indicate that a limited amount of the Cry34Ab1 and Cry35Ab1 proteins 
enters the environment due to expression in the grains (mean value of 45.7 and 1.61µg/g d.w., 
respectively). In addition, the data show that at least 99% of microbially produced Cry34Ab1 and 
Cry35Ab1 proteins were rapidly degraded in simulated gastric fluid.  
 
In conclusion, the VKM GMO Panel considers that the exposure of potentially non-target organisms 
to the binary Cry34Ab1 and Cry35Ab1 proteins is likely to be very low and of no biological relevance. 
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5.5 Potential interactions with the abiotic environment and biochemical 
cycles 
 
Considering the intended uses of maize 59122 x NK603, which exclude cultivation, and the low level 
of exposure to the environment, potential interactions of the GM plant with the abiotic environment 
and biogeochemical cycles were not considered an issue by the VKM GMO Panel. 
 
 
5.6 Post-market environmental monitoring  
 
Directive 2001/18/EC introduces an obligation for applicants to implement monitoring plans, in order 
to trace and identify any direct or indirect, immediate, delayed or unanticipated effects on human 
health or the environment of GMOs as or in products after they have been placed on the market. 
Monitoring plans should be designed according to Annex VII of the Directive. According to Annex 
VII, the objectives of an environmental monitoring plan are 1) to confirm that any assumption 
regarding the occurrence and impact of potential adverse effects of the GMO or its use in the 
environmental risk assessment (ERA) are correct, and (2) to identify the occurrence of adverse effects 
of the GMO or its use on human health or the environment which were not anticipated in the 
environmental risk assessment. 
 
Post-market environmental monitoring is composed of case-specific monitoring and general 
surveillance (EFSA 2011c). Case-specific monitoring is not obligatory, but may be required to verify 
assumptions and conclusions of the ERA, whereas general surveillance is mandatory, in order to take 
account for general or unspecific scientific uncertainty and any unanticipated adverse effects 
associated with the release and management of a GM plant. Due to different objectives between case-
specific monitoring and general surveillance, their underlying concepts differ. Case-specific 
monitoring should enable the determination of whether and to what extent adverse effects anticipated 
in the environmental risk assessment occur during the commercial use of a GM plant, and thus to 
relate observed changes to specific risks. It is triggered by scientific uncertainty that was identified in 
the ERA. 
 
The objective of general surveillance is to identify unanticipated adverse effects of the GM plant or its 
use on human health and the environment that were not predicted or specifically identified during the 
ERA. In contrast to case-specific monitoring, the general status of the environment that is associated 
with the use of the GM plant is monitored without any preconceived hypothesis, in order to detect any 
possible effects that were not anticipated in the ERA, or that are long-term or cumulative.  
 
No specific environmental impact of genetically modified maize 59122 x NK603 was indicated by the 
environmental risk assessment and thus no case specific monitoring is required. The VKM GMO 
Panel is of the opinion that the scope of the monitoring plan provided by the applicant is in line with 
the intended uses of maize NK603 since the environmental risk assessment did not cover cultivation 
and identified no potential adverse environmental effects.  
 
 
5.7  Conclusion 
 
The scope of the application EFSA/GMO/NL/2005/20 includes import and processing of maize 59122 
x NK603 for food and feed uses. Considering the intended uses of maize 59122 x NK603, excluding 
cultivation, the environmental risk assessment is concerned with accidental release into the 
environment of viable grains during transportation and processing, and indirect exposure, mainly 
through manure and faeces from animals fed grains from maize 59122 x NK603.  
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Maize 59122 x NK603 has no altered survival, multiplication or dissemination characteristics, and 
there are no indications of an increased likelihood of spread and establishment of feral maize plants in 
the case of accidental release into the environment of seeds from maize 59122 x NK603. Maize is the 
only representative of the genus Zea in Europe, and there are no cross-compatible wild or weedy 
relatives outside cultivation. The risk of gene flow from occasional feral GM maize plants to 
conventional maize varieties is negligible. Considering the intended use as food and feed, interactions 
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6 Data gaps  
 
Adjuvanticity   
 
There are many knowledge gaps related to assessment of adjuvants. Most of the immunologic 
adjuvant experiments have been performed using Cry1Ac. Whether the other Cry proteins have similar 
adjuvant properties is unknown.  
 
The quantities of Cry proteins in genetically modified maize and soya are marginal compared with the 
amounts of other adjuvants that are natural components of food. However, the extent to which these 
naturally occurring adjuvants and Cry proteins contribute to the development of allergies is largely 
unknown. Determination of their importance is hampered by the lack of validated methods for 
measuring adjuvant effects.  
 
The possibility that Cry proteins might increase the permeability of the intestinal epithelium and 
thereby lead to "bystander" sensitization to strong allergens in the diet of genetically susceptible 
individuals cannot be completely excluded. This possibility could be explored in a relevant animal 
model.  
 
One element of uncertainty in exposure assessment is the lack of knowledge concerning exposure via 
the respiratory tract and the skin, and also the lack of quantitative understanding of the relationship 
between the extent of exposure to an adjuvant and its effects in terms of development of allergies. 
 
 
Herbicide residue levels  
Herbicide residue levels on plants with engineered resistance to one or two broad spectrum herbicides 
could entail higher levels of herbicide residue cocktails compared to plants produced by conventional 
farming practice. 
 
Since it is difficult to predict the toxicity of cocktails from the toxicity of the single components, there 
is uncertainty related to risk of confounding effects such as additive or synergistic effects between the 
residues in herbicide resistant plants.   
 
The transgene technology used can possibly lead to different metabolic products of the applied 
herbicides from what is expected from conventional usage. The risk assessment of herbicides 
should take into account plants with altered metabolism.  
 
At present the changes related to herbicide residues of stacked plants as a result of the application 
















Molecular characterisation  
Southern and PCR analyses has been performed and indicate that the recombinant inserts in the single 
maize events 59122 and NK603 are retained in maize stack 59122xNK603. Genetic stability of the 
inserts has previously been demonstrated in the parental lines 59122 and NK603. The level of 
Cry34Ab1/Cry35Ab1, PAT and CP4 EPSPS proteins in seed and forage from the stacked event were 
measured using ELISA and are comparable to the levels in the single events. Phenotypic analyses also 




Comparative analyses of data from field trials located at representative sites and environments in 
North America indicate that maize stack 59122 x NK603 is compositionally, agronomically and 
phenotypically equivalent to its conventional counterpart, with the exception of the introduced insect 
resistance and herbicide tolerance, conferred by the expression of the Cry34Ab1, Cry35Ab1, PAT and 
CP4 EPSPS proteins. Based on the assessment of available data, the VKM GMO Panel is of the 
opinion that conventional crossing of maize 59122 and NK603 to produce the hybrid 59122 x NK603 
does not result in interactions that cause compositional, agronomic and phenotypic changes that would 
raise safety concerns.  
 
 
Food and feed risk assessment 
Whole food feeding study has not been performed using 59122 x NK603 maize.  The applicant has, 
however, provided a nutritional study on broilers using the triple stacked event 59122 x 1507 x NK603 
maize as test material. Bioinformatics analyses have not revealed expression of any known ORFs in 
the parental maize lines, and none of the newly expressed proteins show resemblance to any known 
toxins or IgE allergens. Nor have the newly expressed proteins been reported to cause IgE mediated 
allergic reactions. Some studies have however indicated a potential role of Cry-proteins as adjuvants 
in allergic reactions. 
 
Acute and repeated toxicity tests in rodents have not indicated toxic effects of the newly expressed 
proteins. However, these tests do not provide any additional information about possible adverse effects 
of the stacked event maize 59122 x NK603. 
 
Based on the current knowledge, the VKM GMO Panel concludes that 59122 x NK603 maize is 
nutritionally equivalent to its conventional maize, and that it is unlikely that newly expressed proteins 
will introduce a toxic or allergenic potential of food/feed derived from maize 59122 x NK603 
compared to conventional maize. 
 
Environmental risk assessment 
The scope of the application EFSA/GMO/UK/2005/21 includes import and processing of maize 59122 
x NK603 for food and feed uses. Considering the intended uses of maize 59122 x NK603, excluding 
cultivation, the environmental risk assessment is concerned with accidental release into the 
environment of viable grains during transportation and processing, and indirect exposure, mainly 
through manure and faeces from animals fed grains from maize 59122 x NK603.  
 
Maize 59122 x NK603 has no altered survival, multiplication or dissemination characteristics, and 
there are no indications of an increased likelihood of spread and establishment of feral maize plants in 
the case of accidental release into the environment of seeds from maize 59122 x NK603. Maize is the 
only representative of the genus Zea in Europe, and there are no cross-compatible wild or weedy 
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relatives outside cultivation. The VKM GMO Panel considers the risk of gene flow from occasional 
feral GM maize plants to conventional maize varieties to be negligible in Norway. Considering the 
intended use as food and feed, interactions with the biotic and abiotic environment are not considered 




The VKM GMO Panel has not identified toxic or altered nutritional properties of maize 59122 x 
NK603 or its processed products compared to conventional maize. Based on current knowledge, it is 
also unlikely that the Cry34Ab1 and Cry35Ab1 protein will increase the allergenic potential of food 
and feed derived from maize 59122 x NK603 compared to conventional maize varieties. The VKM 
GMO Panel likewise concludes that maize 59122 x NK603, based on current knowledge, is 
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Table 1. Summary Analysis of Proximates and Fiber in Forage for the 59122 x NK603 + 
Glyphosate and Control Hybrids (North America 2003) 
 
 
Table 2. Summary Analysis of Minerals in Forage for the 59122 x NK603 + Glyphosate and 











EFSA/GMO/UK/2005/20 – Genetically modified maize 59122 x NK603 
 
Table 3. Literature Ranges of Proximates, Fiber and Mineral in Forage 
 
 
Table 4. Summary Analysis of Proximates and Fiber in Grain for the 59122 x NK603 + 
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Table 5. Summary Analysis of Proximates and Fiber in Grain for the 59122 x NK603 + 
Glufosinate and Control Hybrids (North America, 2003) 
 
 
Table 6. Summary of Analysis of Proximates and Fiber in Grain for the 59122 x NK603 + 
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Table 8. Summary Analysis of Fatty Acids in Grain for the 59122 x NK603 + Glyphosate and 
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Table 9. Summary Analysis of Fatty Acids in Grain for the 59122 x NK603 + Glufosinate and 





Table 10. Summary of Analysis of Fatty Acids in Grain for the 59122 x NK603 + Glyphosate fb 












EFSA/GMO/UK/2005/20 – Genetically modified maize 59122 x NK603 
 
 













































EFSA/GMO/UK/2005/20 – Genetically modified maize 59122 x NK603 
 
Table 12. Summary Analysis of Amino Acids in Grain for the 59122 x NK603 + Glyphosate and 
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Table 13. Summary Analysis of Amino Acids in Grain for the 59122 x NK603 + Glufosinate and 
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Table 14. Summary of Analysis of Amino Acids in Grain for the 59122 x NK603 + Glyphosate fb 
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Table 16. Summary Analysis of Minerals in Grain for the 59122 x NK603 + Glyphosate and 





Table 17. Summary Analysis of Minerals in Grain for the 59122 x NK603 + Glufosinate and 
Control Hybrids (North America 2003) 
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Table 18. Summary of Analysis of Minerals in Grain for the 59122 x NK603 + Glyphosate fb 




Table 19. Literature Ranges of Minerals in Grain  
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Table 20. Summary Analysis of Vitamins in Grain for the 59122 x NK603 + Glyphosate and 
Control Hybrids (North America 2003) 
 
 
Table 21. Summary Analysis of Vitamins in Grain for the 59122 x NK603 + Glufosinate and 
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Table 22. Summary of Analysis of Vitamins in Grain for the 59122 x NK603 + Glyphosate fb 
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Table 24. Summary Analysis of Secondary Metabolites in Grain for the 59122 x NK603 + 
Glyphosate and Control Hybrids (North America 2003) 
 
 
Table 25. Summary Analysis of Secondary Metabolites in Grain for the 59122 x NK603 + 
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Table 26. Summary of Secondary Metabolites Analysis of in Grain for the 59122 x NK603 + 
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Table 28. Summary Analysis of Anti-Nutrients in Grain for the 59122 x NK603 + Glyphosate 





Table 29. Summary Analysis of Anti-Nutrients in Grain for the 59122 x NK603 + Glufosinate 
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Table 30. Summary of Analysis of Anti-Nutrients in Grain for the 59122 x NK603 + Glyphosate 














Table 32. Agronomic data (per location and across locations data) from maize stack 59122 x NK603, sprayed with glyphosate herbicide followed by 
glufosinate herbicide, and from non-GM control maize with comparable genetic background. Data from field trials at five locations in USA and one 
location in Canada (2003 growing season). 
 
